电针抗抑郁的临床疗效及机制研究
摘要
电针抗抑郁的临床疗效及机制研究
研究背景
随着现代社会工作和生活节奏不断加快,竞争等应激事件日益增加,人们承受的心理压力也日益增大。无论是发达国家还是发展中的中国,心理健康问题越来越严重,其中以抑郁症(depression)的发病率上升最为明显。抑郁症是目前临床上常见的、难治性的疾病,是由各种原因引起的以抑郁心境自我体验为中心的临床症状群或状态,严重危害人们的心身健康。针灸治疗抑郁症由来已久,以其疗效确实,无明显副作用为特点。因此如何发挥针灸治疗抑郁症的优势,揭示针灸治疗抑郁症的机理,从而进一步提高抑郁症的治疗效果,是亟待深入探索的问题。
目的
1.对照研究三种方案即电针、百优解、电针+百优解治疗轻、中度抑郁症的临床疗效、起效时间、安全性及预后。
2.对志愿者进行1H-MRS检查,比较健康成人脑海马、前额叶代谢物质的相对浓度,确定其分布特点,为抑郁症的脑MRS研究提供参照依据。
3.对抑郁症患者脑海马、前额叶的NAA, Cho, Cr物质进行1H-MRS定量分析,探讨治疗前后抑郁症患者脑内代谢物质的变化特点,为抑郁症神经生化基础研究提供线索,为临床诊断提供依据。
4.利用磁共振成像和波谱分析,整体、动态地观察三种方案干预状态下抑郁症患者脑功能活动的各项指标及其与抑郁量表评价的相互关联性;寻找抑郁症的临床常见中医证型磁共振检查可能存在的差异,为电针广泛应用于临床治疗抑郁症提供理论准备。
方法
1.将75例轻、中度抑郁症患者采用实用型随机分为A组(百优解组)、B组(电针组)、C组(百优解+电针组),各组间在年龄与性别构成上无统计学差异。采用HAMD抑郁量表、SDS抑郁自评量表评定临床疗效,起效时间、有效率和复发率,TESS副反应量表评定药物不良反应。
2.健康志愿者20例,采用GE EXCITE II Signa 3.OT磁共振系统,PROBE-J序列进行单体素采集,感兴趣区(ROI)分别置于左、右两侧海马和额叶。比较男女间NAA/Cho、NAA/ Cr和Cho/ Cr值的差异。
3.三组抑郁症患者,采用GEEXCITE II Signa 3.OT磁共振系统,PROBE-J序列进行单体素采集,感兴趣区分别置于左、右两侧海马和额叶。比较3组与正常对照组间以及治疗前后NAA/Cho、NAA/ Cr和Cho/ Cr值的差异;比较中医4型与正常对照组间以及治疗前后NAA/Cho、NAA/ Cr和Cho/ Cr值的差异。
结果
1.百优解+电针组临床控制率29.17%及总有效率91.67%明显优于电针组(临床控制率21.74%,总有效率82.61%),以及百优解组(临床控制率17.39%,总有效率78.26%),差异有显著性意义(P<0.05)。
2.三组患者治疗后HAMD、SDS均分数较治疗前明显下降,治疗前后自身比较差异有非常显著性的意义(P<0.01)。治疗后百优解+电针组与电针组、百优解组比较差异有显著性意义(P<0.05)。说明3种治疗方法均有一定改善抑郁症患者临床症状的作用,但百优解+电针组明显优于电针组及百优解组。
3.百优解+电针组在治疗2周后HAMD评分较治疗前的差异有显著性意义(P<0.05)。电针组从治疗4周后HAMD评分较治疗前的差异有显著性意义(P<0.05),百优解组从治疗5周后HAMD评分较治疗前的差异有显著性意义(P<0.05)。说明百优解+电针组起效最快,百优解组起效最慢。
4.电针组、百优解+电针组的躯体症状、睡眠障碍因子分较治疗前的差异有极显著性意义(P<0.01)。百优解组、百优解+电针组的抑郁迟滞因子分较治疗前的差异有显著性意义(P<0.05)。电针在改善躯体症状、睡眠障碍方面有优势,百优解在改善抑郁迟滞方面有优势。
5.百优解+电针组的药物副作用明显较百优解组轻,严重度评分明显逐渐减少,说明百优解+电针组的综合治疗显著减轻了百优解的副反应。百优解+电针组复发率较百优解组明显减少,差异有显著性意义(P<0.05)。
6.按中医辩证分组疗效显示,肝郁气滞型临床控制率最高,疗效最显著,肝肾阴虚型疗效较差,差异有非常显著性意义(P<0.01)。
7.健康志愿者男、女性别之间的两侧额叶、海马NAA/Cho、NAA/ Cr和Cho/ Cr值比较不存在统计学差异(P>0.05)。
8.治疗前三组患者双侧海马的NAA/Cr值较对照组明显减低,双侧额叶的Cho/ Cr值较对照组明显增高,差异有显著性意义(P<0.05)。治疗后电针组双侧海马、百优解+电针组右侧海马的NAA/Cr值较治疗前增高,差异在统计学上有显著性意义(P<0.05),百优解+电针组左海马的NAA/Cr值较治疗前明显增高,差异有非常显著性意义(P<0.01);治疗后百优解组、电针组双侧额叶的Cho/ Cr值较治疗前减低,差异有显著性意义(P<0.05)。百优解+电针组双侧额叶的Cho/ Cr值较治疗前明显减低,差异有非常显著性意义(P<0.01)。
9.治疗前肝郁脾虚型、心脾两虚型、肝肾阴虚型抑郁症双侧海马NAA/ Cr、双侧前额叶Cho/ Cr与对照组的差异有显著性意义(P<0.05);而肝郁气滞型双侧海马NAA/ Cr、双侧前额叶Cho/ Cr与对照组比较,其差异在统计学上无显著性意义。说明治疗前肝郁气滞型(实证)抑郁症与对照组1H-MRS检测的代谢物比值之间没有显著性差异,而其他三型抑郁症(虚证)与对照组之间有显著性差异,其结果与肝郁气滞型抑郁症患者病例数相对少,病程相对短,病情相对较轻有一定关系,1H-MRS检测的代谢物比值是否能区别抑郁症中医分型的实证与虚证,仍需大样本进一步证实。
治疗后心脾两虚型、肝郁脾虚型双侧海马NAA/ Cr、双侧前额叶Cho/ Cr与治疗前的差异有显著性意义(P<0.05);而治疗后肝肾阴虚型双侧海马NAA/ Cr、双侧前额叶Cho/ Cr与治疗前比较,其差异无显著性意义。说明治疗后肝郁脾虚型、心脾两虚型效果显著,与对照组之间没有显著性差异,而肝肾阴虚型疗效不佳,与对照组的差异仍有显著性差异。其结果与肝肾阴虚型抑郁症患者病程相对长,病情相对较重有一定关系,仍需大样本进一步证实。
结论
1.电针能明显改善抑郁症的躯体症状,起效快,减轻百优解的不良反应,百优解+电针治疗轻、中度抑郁症疗效好,不良反应少,复发率低,是值得临床推广的较优化治疗方案。
2.1H-MRS能较准确的显示NAA, Cho, Cr等代谢物的波谱,是了解脑内生化信息的一种有重要价值的方法。正常成人额叶、海马间的代谢物浓度存在差异,这些差异反映了相应部位组织学结构的不同。
3.抑郁症患者两侧额叶、海马与正常成人相应部位的代谢物浓度存在差异,从本质上揭示了抑郁症的发生机制。三种方案干预前后抑郁症患者脑功能活动的各项指标及其与抑郁量表评价的一致性,临床常见中医证型磁共振检查亦存在着差异,为抑郁症临床诊断及疗效评价提供了一种新的探索手段。
Background
In the fast paced modern society, people are bearing much psychological pressure. In both developed and developing countries including China, mental health problems are becoming more and more serious. Among which, the high incidence of depression should be pay more attention to. Depression is a popular and refractory disease, which seriously endangers people's physical and mental health. It has a long history of acupuncture treatment for depression, which characterized by its significant effectiveness and no side effects. Therefore, it is an urgent task for us to show its advantages and discover its mechanisms and then improve it.
Object
1. Find out the different effect, the onset time, the security and the prognosis of there different plans for depression, which are EA, fluoxetine and EA+ fluoxetine.
2. To take the 1H‐MRS exam of the consistence of the metabolic matters in hippocampus and prefrontal lobe of the healthy volunteers and definite the matters’location. This can Provides reference basis for depression research.
3. To take the quantitative analysis of the NAA, Cho, Cr of the hippocampus and prefrontal lobe of the depression patients. To explore the changes between treatment and after treatment of the depression patients. This can provides evidence for the clinical treatment.
4. Use MRI and MRS methods to evaluate the three different treatment methods holistically and dynamically. To find out the relationship between these iconography indexes and the depression scales. By doing this we can combine the different type of the TCM differentiation according to the syndromes with the image methods in order to provide theoretic basis for EA to depression.
Method
1. 75 minor and mild depression patients were divided into three groups, which are A (fluoxetine group), B (EA group), C (fluoxetine+ EA group). There is no significant difference in those three groups in the age and sex. Use HAMD, SDS to evaluate the clinical effective rate, the onset time and the recurernce rate; while use TESS scale to evaluate the untoward effect.
2. Use PROBE‐J sequence at GE EXCITE II Signa 3.OT MRI system on Single Voxel of the ROI of bilateral hippocampus and frontal lobe of 20 healthy volunteers. Compare differences of the NAA/Cho, NAA/ Cr and Cho/ Cr between men and wemen.
3. Use PROBE‐J sequence at GE EXCITE II Signa 3.OT MRI system on Single Voxel of the ROI of each lateral hippocampus and frontal lobe depression patients of the three groups. Compare the differences of NAA/Cho, NAA/ Cr and Cho/ Cr between the healthy volunteers and the patients and also the patients before treatment and after treatment. In addition, compare the differences of NAA/Cho, NAA/ Cr and Cho/ Cr between the different TCM syndrome differentiation types.
Result
1. The control rate of C (fluoxetine+ EA group) is 29.17% and the effective rate is 91.67% which is much significantly higher than the A (fluoxetine group) with the control rate of 17.39% and the effective rate of 78.26%, B (EA group) with the control rate of 21.74%and the effective rate of 82.61%(P<0.05).
2. Compared with the average before treatment, the HAMD and SDS average of the patients in the three groups significantly decreased after treatmen(tP<0.01). And the C (fluoxetine+ EA group) showed a significant difference with the A (fluoxetine group) and B (EA group) (P<0.05).This may suggest the preferable effectiveness of the C (fluoxetine+ EA group) than the other two groups.
3. The significant difference(P<0.05) between before treatment and after treatment of C (fluoxetine+ EA group) started from the second week. While it happened to B (EA group) (P<0.05) from the fourth week and the A (fluoxetine group), the fifth week. This indicates that fluoxetine with EA together function most quickly and the fluoxetine only function most slowly.
4. There were significant differences between before treatment and after treatment in somatization syndromes and the somnipathy factor scores of the B (EA group) and C (fluoxetine+ EA group) (P<0.01). There were significant differences between before treatment and after treatment in retarded factor scores of the B (EA group) and C (fluoxetine+ EA group)(P<0.05). This may indicate that EA is more effective in improving the somatization syndromes and he somnipathy while the fluoxetine is more effective in retarded depression.
5. The side effect of the C (fluoxetine+ EA group) was much less than the A (fluoxetine group), which indicate that fluoxetine with EA together can alleviate the side effect of the fluoxetine only. The recurernce rateof the C (fluoxetine+ EA group) is significantly decreased than A (fluoxetine group) (P<0.05).
6. The effective rate of Liver‐depression is significantly higher than the hepatic and renal yin deficiency type depression.(P<0.01).
7. There were no significant differences between the men and women in NAA/Cho, NAA/ Cr and Cho/ Cr in each lateral hippocampus and frontal lobe.
8. There were a significant decrease of the NAA/Cr in bilateral hippocampus and a significant increase of the Cho/ Cr of the bilateral frontal lobe of the depression patients in the three groups before treatment(P<0.05).
The NAA/Cr in bilateral hippocampus of B (EA group) and the NAA/Cr of the right hippocampus of C (fluoxetine+ EA group) increased significantly(P<0.05),the NAA/Cr of the left hippocampus of C (fluoxetine+ EA group) increased very significantly(P<0.01). The Cho/ Cr of the bilateral frontal lobe of A(fluoxetine group) and B (EA group) decreased significantly after treatment(P<0.05). The Cho/ Cr of the bilateral frontal lobe of C (fluoxetine+ EA group) decreased very significantly after treatment(P<0.01)。
9.There were significant differences in NAA/ Cr of bilateral hippocampus and Cho/ Cr of bilateral frontal lobe between Liver‐depression and Spleen‐deficiency type, Deficiency of both Heart and Spleen type and hepatic and renal yin deficiency type depression patients and healthy volunteers (P<0.05);While there were no significant differences in NAA/ Cr of bilateral hippocampus and Cho/ Cr of bilateral frontal lobe between Liver Stagnation type depression patients and healthy volunteers. The Liver Stagnation type depression patients is less than the other three groups and their course of disease is respectively shorter and patient's condition is better than the other three types. This may suggest that the different TCM syndrome differentiation type may relate to their metabolism. This result needs further study.
There were significant differences in NAA/ Cr of bilateral hippocampus and Cho/ Cr of bilateral frontal lobe between Liver‐depression and Spleen‐deficiency type and Deficiency of both Heart and Spleen type depression patients and healthy volunteers after treatment(P<0.05); While there were no significant differences in NAA/ Cr of bilateral hippocampus and Cho/ Cr of bilateral frontal lobe in hepatic and renal yin deficiency type depression patients between before treatment and after treatment. This may indicate that the treatment is more effective to the Liver‐depression and Spleen‐deficiency type, Deficiency of both Heart and Spleen type and Liver Stagnation type than to hepatic and renal yin deficiency type depression patients. This may because the long course of disease and severe patient's condition. This result needs further study.
Conclusion
1. EA can alleviate the somatization of the depression patients and the side effects of the fluoxetine, EA with fluoxetine together is a prominent treatment for depression for its small side effect and recurernce rate.
2. 1H‐MRS can reflect the spectrum of NAA, Cho and Cr accurately,so it is a valuable method to detect the biochemistry changes in brain. There is different in the density of the metabolite in frontal lobe and hippocampus of common adults, which may reflect their structural differences.
3. There is difference between depression patients and common people in the density of the metabolite in frontal lobe and hippocampus, which may relate to the nosogenesis of depression. The changes of those scales and MRI index before and after those three treatment and their relation between different TCM syndrome differentiation type would provide new method to explore the treatment and evaluation of depression.
研究背景
随着现代社会工作和生活节奏不断加快,竞争等应激事件日益增加,人们承受的心理压力也日益增大。无论是发达国家还是发展中的中国,心理健康问题越来越严重,其中以抑郁症(depression)的发病率上升最为明显。抑郁症是目前临床上常见的、难治性的疾病,是由各种原因引起的以抑郁心境自我体验为中心的临床症状群或状态,严重危害人们的心身健康。针灸治疗抑郁症由来已久,以其疗效确实,无明显副作用为特点。因此如何发挥针灸治疗抑郁症的优势,揭示针灸治疗抑郁症的机理,从而进一步提高抑郁症的治疗效果,是亟待深入探索的问题。
目的
1.对照研究三种方案即电针、百优解、电针+百优解治疗轻、中度抑郁症的临床疗效、起效时间、安全性及预后。
2.对志愿者进行1H-MRS检查,比较健康成人脑海马、前额叶代谢物质的相对浓度,确定其分布特点,为抑郁症的脑MRS研究提供参照依据。
3.对抑郁症患者脑海马、前额叶的NAA, Cho, Cr物质进行1H-MRS定量分析,探讨治疗前后抑郁症患者脑内代谢物质的变化特点,为抑郁症神经生化基础研究提供线索,为临床诊断提供依据。
4.利用磁共振成像和波谱分析,整体、动态地观察三种方案干预状态下抑郁症患者脑功能活动的各项指标及其与抑郁量表评价的相互关联性;寻找抑郁症的临床常见中医证型磁共振检查可能存在的差异,为电针广泛应用于临床治疗抑郁症提供理论准备。
方法
1.将75例轻、中度抑郁症患者采用实用型随机分为A组(百优解组)、B组(电针组)、C组(百优解+电针组),各组间在年龄与性别构成上无统计学差异。采用HAMD抑郁量表、SDS抑郁自评量表评定临床疗效,起效时间、有效率和复发率,TESS副反应量表评定药物不良反应。
2.健康志愿者20例,采用GE EXCITE II Signa 3.OT磁共振系统,PROBE-J序列进行单体素采集,感兴趣区(ROI)分别置于左、右两侧海马和额叶。比较男女间NAA/Cho、NAA/ Cr和Cho/ Cr值的差异。
3.三组抑郁症患者,采用GEEXCITE II Signa 3.OT磁共振系统,PROBE-J序列进行单体素采集,感兴趣区分别置于左、右两侧海马和额叶。比较3组与正常对照组间以及治疗前后NAA/Cho、NAA/ Cr和Cho/ Cr值的差异;比较中医4型与正常对照组间以及治疗前后NAA/Cho、NAA/ Cr和Cho/ Cr值的差异。
结果
1.百优解+电针组临床控制率29.17%及总有效率91.67%明显优于电针组(临床控制率21.74%,总有效率82.61%),以及百优解组(临床控制率17.39%,总有效率78.26%),差异有显著性意义(P<0.05)。
2.三组患者治疗后HAMD、SDS均分数较治疗前明显下降,治疗前后自身比较差异有非常显著性的意义(P<0.01)。治疗后百优解+电针组与电针组、百优解组比较差异有显著性意义(P<0.05)。说明3种治疗方法均有一定改善抑郁症患者临床症状的作用,但百优解+电针组明显优于电针组及百优解组。
3.百优解+电针组在治疗2周后HAMD评分较治疗前的差异有显著性意义(P<0.05)。电针组从治疗4周后HAMD评分较治疗前的差异有显著性意义(P<0.05),百优解组从治疗5周后HAMD评分较治疗前的差异有显著性意义(P<0.05)。说明百优解+电针组起效最快,百优解组起效最慢。
4.电针组、百优解+电针组的躯体症状、睡眠障碍因子分较治疗前的差异有极显著性意义(P<0.01)。百优解组、百优解+电针组的抑郁迟滞因子分较治疗前的差异有显著性意义(P<0.05)。电针在改善躯体症状、睡眠障碍方面有优势,百优解在改善抑郁迟滞方面有优势。
5.百优解+电针组的药物副作用明显较百优解组轻,严重度评分明显逐渐减少,说明百优解+电针组的综合治疗显著减轻了百优解的副反应。百优解+电针组复发率较百优解组明显减少,差异有显著性意义(P<0.05)。
6.按中医辩证分组疗效显示,肝郁气滞型临床控制率最高,疗效最显著,肝肾阴虚型疗效较差,差异有非常显著性意义(P<0.01)。
7.健康志愿者男、女性别之间的两侧额叶、海马NAA/Cho、NAA/ Cr和Cho/ Cr值比较不存在统计学差异(P>0.05)。
8.治疗前三组患者双侧海马的NAA/Cr值较对照组明显减低,双侧额叶的Cho/ Cr值较对照组明显增高,差异有显著性意义(P<0.05)。治疗后电针组双侧海马、百优解+电针组右侧海马的NAA/Cr值较治疗前增高,差异在统计学上有显著性意义(P<0.05),百优解+电针组左海马的NAA/Cr值较治疗前明显增高,差异有非常显著性意义(P<0.01);治疗后百优解组、电针组双侧额叶的Cho/ Cr值较治疗前减低,差异有显著性意义(P<0.05)。百优解+电针组双侧额叶的Cho/ Cr值较治疗前明显减低,差异有非常显著性意义(P<0.01)。
9.治疗前肝郁脾虚型、心脾两虚型、肝肾阴虚型抑郁症双侧海马NAA/ Cr、双侧前额叶Cho/ Cr与对照组的差异有显著性意义(P<0.05);而肝郁气滞型双侧海马NAA/ Cr、双侧前额叶Cho/ Cr与对照组比较,其差异在统计学上无显著性意义。说明治疗前肝郁气滞型(实证)抑郁症与对照组1H-MRS检测的代谢物比值之间没有显著性差异,而其他三型抑郁症(虚证)与对照组之间有显著性差异,其结果与肝郁气滞型抑郁症患者病例数相对少,病程相对短,病情相对较轻有一定关系,1H-MRS检测的代谢物比值是否能区别抑郁症中医分型的实证与虚证,仍需大样本进一步证实。
治疗后心脾两虚型、肝郁脾虚型双侧海马NAA/ Cr、双侧前额叶Cho/ Cr与治疗前的差异有显著性意义(P<0.05);而治疗后肝肾阴虚型双侧海马NAA/ Cr、双侧前额叶Cho/ Cr与治疗前比较,其差异无显著性意义。说明治疗后肝郁脾虚型、心脾两虚型效果显著,与对照组之间没有显著性差异,而肝肾阴虚型疗效不佳,与对照组的差异仍有显著性差异。其结果与肝肾阴虚型抑郁症患者病程相对长,病情相对较重有一定关系,仍需大样本进一步证实。
结论
1.电针能明显改善抑郁症的躯体症状,起效快,减轻百优解的不良反应,百优解+电针治疗轻、中度抑郁症疗效好,不良反应少,复发率低,是值得临床推广的较优化治疗方案。
2.1H-MRS能较准确的显示NAA, Cho, Cr等代谢物的波谱,是了解脑内生化信息的一种有重要价值的方法。正常成人额叶、海马间的代谢物浓度存在差异,这些差异反映了相应部位组织学结构的不同。
3.抑郁症患者两侧额叶、海马与正常成人相应部位的代谢物浓度存在差异,从本质上揭示了抑郁症的发生机制。三种方案干预前后抑郁症患者脑功能活动的各项指标及其与抑郁量表评价的一致性,临床常见中医证型磁共振检查亦存在着差异,为抑郁症临床诊断及疗效评价提供了一种新的探索手段。
Background
In the fast paced modern society, people are bearing much psychological pressure. In both developed and developing countries including China, mental health problems are becoming more and more serious. Among which, the high incidence of depression should be pay more attention to. Depression is a popular and refractory disease, which seriously endangers people's physical and mental health. It has a long history of acupuncture treatment for depression, which characterized by its significant effectiveness and no side effects. Therefore, it is an urgent task for us to show its advantages and discover its mechanisms and then improve it.
Object
1. Find out the different effect, the onset time, the security and the prognosis of there different plans for depression, which are EA, fluoxetine and EA+ fluoxetine.
2. To take the 1H‐MRS exam of the consistence of the metabolic matters in hippocampus and prefrontal lobe of the healthy volunteers and definite the matters’location. This can Provides reference basis for depression research.
3. To take the quantitative analysis of the NAA, Cho, Cr of the hippocampus and prefrontal lobe of the depression patients. To explore the changes between treatment and after treatment of the depression patients. This can provides evidence for the clinical treatment.
4. Use MRI and MRS methods to evaluate the three different treatment methods holistically and dynamically. To find out the relationship between these iconography indexes and the depression scales. By doing this we can combine the different type of the TCM differentiation according to the syndromes with the image methods in order to provide theoretic basis for EA to depression.
Method
1. 75 minor and mild depression patients were divided into three groups, which are A (fluoxetine group), B (EA group), C (fluoxetine+ EA group). There is no significant difference in those three groups in the age and sex. Use HAMD, SDS to evaluate the clinical effective rate, the onset time and the recurernce rate; while use TESS scale to evaluate the untoward effect.
2. Use PROBE‐J sequence at GE EXCITE II Signa 3.OT MRI system on Single Voxel of the ROI of bilateral hippocampus and frontal lobe of 20 healthy volunteers. Compare differences of the NAA/Cho, NAA/ Cr and Cho/ Cr between men and wemen.
3. Use PROBE‐J sequence at GE EXCITE II Signa 3.OT MRI system on Single Voxel of the ROI of each lateral hippocampus and frontal lobe depression patients of the three groups. Compare the differences of NAA/Cho, NAA/ Cr and Cho/ Cr between the healthy volunteers and the patients and also the patients before treatment and after treatment. In addition, compare the differences of NAA/Cho, NAA/ Cr and Cho/ Cr between the different TCM syndrome differentiation types.
Result
1. The control rate of C (fluoxetine+ EA group) is 29.17% and the effective rate is 91.67% which is much significantly higher than the A (fluoxetine group) with the control rate of 17.39% and the effective rate of 78.26%, B (EA group) with the control rate of 21.74%and the effective rate of 82.61%(P<0.05).
2. Compared with the average before treatment, the HAMD and SDS average of the patients in the three groups significantly decreased after treatmen(tP<0.01). And the C (fluoxetine+ EA group) showed a significant difference with the A (fluoxetine group) and B (EA group) (P<0.05).This may suggest the preferable effectiveness of the C (fluoxetine+ EA group) than the other two groups.
3. The significant difference(P<0.05) between before treatment and after treatment of C (fluoxetine+ EA group) started from the second week. While it happened to B (EA group) (P<0.05) from the fourth week and the A (fluoxetine group), the fifth week. This indicates that fluoxetine with EA together function most quickly and the fluoxetine only function most slowly.
4. There were significant differences between before treatment and after treatment in somatization syndromes and the somnipathy factor scores of the B (EA group) and C (fluoxetine+ EA group) (P<0.01). There were significant differences between before treatment and after treatment in retarded factor scores of the B (EA group) and C (fluoxetine+ EA group)(P<0.05). This may indicate that EA is more effective in improving the somatization syndromes and he somnipathy while the fluoxetine is more effective in retarded depression.
5. The side effect of the C (fluoxetine+ EA group) was much less than the A (fluoxetine group), which indicate that fluoxetine with EA together can alleviate the side effect of the fluoxetine only. The recurernce rateof the C (fluoxetine+ EA group) is significantly decreased than A (fluoxetine group) (P<0.05).
6. The effective rate of Liver‐depression is significantly higher than the hepatic and renal yin deficiency type depression.(P<0.01).
7. There were no significant differences between the men and women in NAA/Cho, NAA/ Cr and Cho/ Cr in each lateral hippocampus and frontal lobe.
8. There were a significant decrease of the NAA/Cr in bilateral hippocampus and a significant increase of the Cho/ Cr of the bilateral frontal lobe of the depression patients in the three groups before treatment(P<0.05).
The NAA/Cr in bilateral hippocampus of B (EA group) and the NAA/Cr of the right hippocampus of C (fluoxetine+ EA group) increased significantly(P<0.05),the NAA/Cr of the left hippocampus of C (fluoxetine+ EA group) increased very significantly(P<0.01). The Cho/ Cr of the bilateral frontal lobe of A(fluoxetine group) and B (EA group) decreased significantly after treatment(P<0.05). The Cho/ Cr of the bilateral frontal lobe of C (fluoxetine+ EA group) decreased very significantly after treatment(P<0.01)。
9.There were significant differences in NAA/ Cr of bilateral hippocampus and Cho/ Cr of bilateral frontal lobe between Liver‐depression and Spleen‐deficiency type, Deficiency of both Heart and Spleen type and hepatic and renal yin deficiency type depression patients and healthy volunteers (P<0.05);While there were no significant differences in NAA/ Cr of bilateral hippocampus and Cho/ Cr of bilateral frontal lobe between Liver Stagnation type depression patients and healthy volunteers. The Liver Stagnation type depression patients is less than the other three groups and their course of disease is respectively shorter and patient's condition is better than the other three types. This may suggest that the different TCM syndrome differentiation type may relate to their metabolism. This result needs further study.
There were significant differences in NAA/ Cr of bilateral hippocampus and Cho/ Cr of bilateral frontal lobe between Liver‐depression and Spleen‐deficiency type and Deficiency of both Heart and Spleen type depression patients and healthy volunteers after treatment(P<0.05); While there were no significant differences in NAA/ Cr of bilateral hippocampus and Cho/ Cr of bilateral frontal lobe in hepatic and renal yin deficiency type depression patients between before treatment and after treatment. This may indicate that the treatment is more effective to the Liver‐depression and Spleen‐deficiency type, Deficiency of both Heart and Spleen type and Liver Stagnation type than to hepatic and renal yin deficiency type depression patients. This may because the long course of disease and severe patient's condition. This result needs further study.
Conclusion
1. EA can alleviate the somatization of the depression patients and the side effects of the fluoxetine, EA with fluoxetine together is a prominent treatment for depression for its small side effect and recurernce rate.
2. 1H‐MRS can reflect the spectrum of NAA, Cho and Cr accurately,so it is a valuable method to detect the biochemistry changes in brain. There is different in the density of the metabolite in frontal lobe and hippocampus of common adults, which may reflect their structural differences.
3. There is difference between depression patients and common people in the density of the metabolite in frontal lobe and hippocampus, which may relate to the nosogenesis of depression. The changes of those scales and MRI index before and after those three treatment and their relation between different TCM syndrome differentiation type would provide new method to explore the treatment and evaluation of depression.
引文
1.金光亮.有关抑郁症季节性发病机理的研究及启示.北京中医药大学学报,1997,20(1):15-16.
2.赵志升,赵敏.抑虑康治疗郁证 180 例疗效观察.山东中医杂志,1999, 18 (3):110-112.
3.刘宝录.解郁汤治疗隐匿性抑郁症31 例体会.天津中医,1999, 8 (1):16-18.
4.赵嘉萍.解郁汤治疗抑郁症.四川中医,1992, 10 (8): 35-36.
5.郭雅明,刘翠峰.王彦恒治疗抑郁症经验.河北中医,2002, 24 (2):100-101.
6.陈日宙.忧郁证从脾肾论治.光明中医杂志,1995, 10 (6): 7-8.
7.胡思荣.平心忘忧汤治疗抑郁症470 例.湖北中医杂志,1996, 18 (2):4-5.
8.郝万山.柴桂温胆定志汤为主治疗精神抑郁症.北京中医药大学学报,1997, 20 (3):64-65.
9.刘兰英.“脑为元神之府”理论在针灸治疗抑郁症中的指导意义.针灸临床杂志,2003, 19 (8):6-9.
10.全世建.百合地黄汤加减治疗抑郁症30 例疗效观察.新中医,1999, 31(2):16-17.
11.陈珠娇.中医治疗老年性抑郁症22 例.福建中医药1998, 29 (6): 22.
12.曲森,唐启盛.抑郁症与中医“郁证”的关系探讨.北京中医药大学学报,2004, 27 (1):11-13.
13. 张泰康.谈老年妇女精神抑郁症的辨治[J].山东中医药杂志1989;8(4):4-6.
14. 张兰柱.浅谈更年期抑郁症的辨证治疗[J].中国中医基础医学杂志 2001;7(7):533-535.
15. 李金瑚.老年期抑郁症从肾论治[J].新中医1990;22(5):54-56.
16. 郝万山,柴桂.温胆定志汤为主治疗精神抑郁[J].北京中医药大学学报 1997;20(3):64-66.
17. 武志平,闫桂玲.自拟补源解郁汤治疗妇女忧郁症 156 例[J].中国民间疗法 1998;10(5):48-50.
18. 许沛虎.中医脑病学.北京:中国医药科技出版社,1998:925-927.
19. 骆方.大钟穴的临床应用[J].浙江中医学院学报,1992,(3):50-52.
20. 刘志顺,刘军,黄漫,等.调理髓海法治疗中风后抑郁症 30 例临床观察[J].中国针灸,1997,(9):543-544.
21.刘志顺,黄石玺,黄漫,等.针刺治疗中风后抑郁症临床研究[J].实用中西医结合杂志,1997,10(11):1038-1039.
22.李建生,张杰,杨戈.中医药治疗老年抑郁症的研究概况[J].河南中医药学刊,2001,16(1):10-13.
23.姜凤莲,马建功.针刺治疗老年期抑郁症[J].河北中医,1997,17(6):373-375.
24.叶国传.针刺治疗抑郁症36 例[J].上海针灸杂志,2000,(6):30-32.
25.费宇彤,杨德强,时宇静,等.近 10 年国际针刺临床文献分析.中国中医药信息杂志,2006,13(4):101-102.
26.蒋振亚,何玲娜,彭力群,等.针刺天谷八阵治疗中风后抑郁症[J].中国针灸,2002,22(1):30-32.
27.费宇彤,杨德强,焦爽,等.近 10 年国际针刺临床病种变化研究.中国中医药信息杂志,2006,13(5):102-103.
28.杨敏,陈晓莉.针灸治疗抑郁症的近况[J].浙江中医杂志,2002,(3):128-129.
27.丁德正.精神病抑郁状态辨治体会[J].陕西中医,1994,(4):191- 192.
28.罗和春.抑郁症的电针合并舒血宁治疗与实验室细胞免疫水平改变的研究[J].美国中华健康卫生杂志,2000,3(2):1-3.
29.马静.针灸治疗抑郁症的临床研究[J].中华现代临床医学杂志,2005; 3 (11):1094-1095.
30.符文彬.针灸对抑郁性神经症的治疗作用[J].中国临床康复,2002; 6 ( 5 ): 679.
31.黄学军,罗仁浩.针刺治疗抑郁性神经症疼痛的疗效[J].广东医学,2000; 20 (8)704.
32.张春红,李金波,王舒.在德国运用“醒脑开窍针刺法”治疗郁证的临床观察[J].针灸临床杂志,2002; 18 (8): 26.
33.刘志顺.调理髓海法治疗中风后抑郁症 30 例临床观察[J].中国针灸,1997; 21(4):200.
34.张中发,王军峰,杜贵平.电针百会印堂穴在精神科的应用[J].中国针灸,2001,(10):633-636.
35.罗和春,沈渔邨,贾云奎.电针治疗 133 例抑郁症患者临床疗效观察[J].中西医结合杂志,1988,(2):77-80.
36.刘广志,贾云桂,詹丽,等.电针治疗早老期,老年期抑郁状态的临床疗效观察[J].中医杂志,1991,(5):36-38.
37.王辉,于恩庆,赵军,等.电针治疗 129 例精神科常见病疗效分析[J].针灸临床杂志,1999,(l):42-44.
38.陈光,周东丰,沈渔村,等.抑郁病人TRH 兴奋试验及实验结果与DST尿MHPG·SO4排出量的关系[J].中华神经精神科杂志;1991,24(4):203-205.
39.周东丰.精神疾病的神经生化基础和电针治疗抑郁症的机理研究[J].电针治疗抑郁症及有关中西医综合新技术资料汇编.北京医科大学精神卫生研究所,1992.18-20.
40.林虹.电针治疗产后精神障碍抑郁型53 例疗效观察[J].天津中医,1996,(2):4-6.
41.侯冬芬,罗和春.电针百会印堂治疗30 例中风后抑郁患者临床疗效观察[J].中国针灸,1996,(8):23-24.
42.杨坤英.电针百会印堂穴治疗抑郁症临床观察[J].天津中医,1998,15(6):124-125.
43.董子平.电针治疗抑郁症101 例[J].中国针灸,2001,(1):6-8.
44.淑莎尼克,图娅.电针与百优解对照治疗抑郁症的临床观察.针刺研究,2006,31(4):242-243.
45.淑莎尼克,图娅.针灸与百优解对照治疗抑郁症的临床研究.中华中西医杂志,2006,7(11):961-964.
46.赵秀敏.背俞穴穴位注射配合针刺治疗郁证[J].中国中医药信息杂志,2001; 8 (12):78.
47.李振芝,洗莉,讳晓晴等.针刺配合离子导入治疗抑郁性神经症258 例临床观察[J].中国针灸,1998; 21(8) : 465.
48.任建宁.耳针治疗抑郁症50 例[J].河南中医,2005; 25 (2 ): 75.
49.秦丽娜,史榕荇.电针对慢性应激抑郁模型大鼠脑肠肽类激素的影响[J].安徽中医学院学报,2007;(1):26.
50.高碧霄.十余年来百会穴研究概况[J].中医文献杂志,1997; (2):41-43.
51.段方胜,吴钢,郑依勇等.针刺四关穴对头痛患者脑血流动力学的影响[J].上海针灸杂志,1996; 15 (2):5.
52.徐虹,孙忠人,李丽萍,等.针刺治疗抑郁症及其对患者下丘脑一垂体一肾上腺轴的影响[J].中国针灸,2004; 24(2): 78.
53.杜元灏,李桂平,颜红,等.调神疏肝针法治疗郁症的临床研究[J].中国针灸,2005;25 (3):151.
54.金光亮,周东丰,苏晶.电针对慢反应应激抑郁模型大鼠单胺类神经递质的影响[J].中国精神科杂志,1999,32(4):220-222.
55.韩毳,李晓泓,李学武,等.电针“百会”、“三阴交”穴对慢性应激抑郁模型大鼠 HPA轴的影响[J].北京中医药大学学报,2001,24(3):74-76.
56.邱艳明,时宇静.电针印堂、百会对获得性无助大鼠不同脑区内单胺类神经递质的影响[J].北京中医药大学学报,2002,25(6):54-56.
57.韩毳,王磊,等.电针对抑郁症患者血清细胞因子的影响[J].中国行为医学科学,2002,11(3)277-279.
58.黄泳,唐安戊,李求实,等.运用 PET 技术研究头电针治疗抑郁症的机理[J].四川中医,2004;22(10):6.
59.俞瑾,李晓艳,曹小定,等.电针合用抗抑郁药能明显减少小鼠强迫游泳实验中的静止时间[J].针刺研究,2002,27(2):119-123.
60.孙华,张有志.针灸百会和足三里穴对抑郁模型小鼠和大鼠行为的影响[J].针灸临床杂志,2003,19(2):47-49.
61.韩毳,李学武,李晓泓,等.电针对慢性应激抑郁模型大鼠海马BDNF 的影响[J].中国中医基础医学杂志,2001,7(7):55-57.29.
1. 江开达,江三多,王红霞等.单相抑郁症中 5-HT2A 受体基因及 MAOA 型基因的相互影响.中国神经精神疾病杂志,1999; 25 (2) :90-92.
2. 王立伟,江三多,汪栋祥等.5-羟色胺6 受体基因多态性与抑郁症的关联研究.中华精神科杂志,2000;33(4):216-217.
3. Van Wi·Jngaarden M Th M,Tulp W Soudijn,The concept of selectivity in 5-HT receptor research,European Journal of Pharmacology- Molecular Pharmacology Section,1990,188:301-312.
4. Zemlan FP,Garver DL.Depression and antide pressant therapy:receptor dynamics [J].Prog Neuropsychopharmacol Biol Psychiatry, 1990,14(4): 503-523.
5. Ehlers CL, Somes C, Seifritz E, et al. CRF/NPY interactions:a potential role in sleep dysregulation in depression and anxiety. Depress Anxiety 1997 6(1):1-9.
6. Antonijevic IA, Murck H, Bohlhalter S, et al. Neuropeptide Y promotes sleep and inhibits ACTH and cortisol release in young men. Neuropharmacology 2000, 39(8):1474-81.
7. Sapolsky RM . Glucocorticoids and hippocampal atrophy in neuropsychiatric disorders . Arch Gen Psychiatry,2000,57:925-935.
8. Paskitti ME , McCreary BJ , Herman JP.Stress regulation of adrenocorticosteroid receptor gene transcription and mRNA expression in rat hippocampus:time-course analysis.Brain Res Mol Brain Res,2000,80:142-152.
9. Lucassen PJ, Muller MB, Holsboer F,et al. Hippocampal apoptosis in major depression is a minor event and absent from subareas at risk for glucocorticoid overexposure.Am J Pathol, 2001,158 :453-468.
10. Zahorodna A,Tokarski K,Bijak M . Electrophysiologic tests for testing the effects of antidepressant drugs and corticosterone on reactivity of serotonin receptors in the hippocampus.Postepy Hig Med Dosw,2000,54:391-401.
11. Frank MG,Hendricks SE,Bessette D.Levels of monocyte reactive oxygen species are associated with reduced natural killer cell activity inmajor depressive disorder.Neuropsychobiology 2001,44(1):1-6.
12. Mizoguchi K,Yuzurihara M,Ishige A,et al.Chronic stress differentially regulates glucocorticoid negative feedback response in rats. Psychoneuroendocrinology,2001,26: 443-459.
13. Peteranderl C, Antonijevic IA, Steiger A, et al. Nocturnal secretion of TSH and ACTH in male patients with depression and healthy controls. J Psychiatr Res 2002, 36(3):189-96.
14. Lloyd RL, Pekary AE, Sattin A, et al. Antidepressant effects of thyrotropin –releasing hormone analogues using a rodent model of depression. Pharmacol Biochem Behav 2001,70(1):15-22.
15.孙士友,舒良,白惠卿等.抑郁症患者细胞免疫功能的研究.中华精神科杂志1998;31(1):23-25.
16. MaddockC,ParianteCM.How dose stress affect you? An overview of stress, immunity, depression and disease.Epidemiol Psychiatr Soc,2001 Jul-Sep,10(3):153-156.
17. Toussaint M, Luthringer R, Staner L, etal.Channges in EEG power density during sleep laboratory adaptation in depressed in patients. BiolPsychiatry, 2000,47:626-633.
18.张心保,侯钢,耿直等.抑郁症及其亚型的睡眠脑电图研究.中华精神科杂志,1999,32(1): 30.
19.Shagass C. Age, personality and somatosensory cerebral evoked responses. Science, 1965, 148:1359-1364.
20.Spehiman R. VEP, AEP and SEP in Clinical Diagnosis. Battrwith Heineman,l985:89-94.
21.林明方,李建军.抑郁症首次发病患者额叶三维磁共振氢质子波分析研究[J]. 中华精神科杂志, 2006 ,1:5-8.
1.林平尔.磁共振在精神医学研究中的应用[J].国外医学精神病学分册.1994.21(4):231-233.
2.崔青,彭昌孝,刘文.抑郁症患者脑的磁共振研究[J].临床精神医学杂志.2001.11(6):344-345.
3.Soares JC,Krishnan KR,Keshavan MS.Nuclear magnetic resonanc espectroscopy : new insights in to the pathophysiology of mood disorders.Depression 1996;4:14.
4.Drevets WC,Price JL,Simpson JK,et al.Subgenual prefrontal cortex abnormalities in mood disorders.Nature 1997;27:824.
5.Sheline YI,Wang PW,Gado MH,et al.Hippocampal atrophy in recurrent major depression.Proc Natl Acad Sci 1996;93(9):3908-3913.
6.Mervaala E,Folhr J,Kgngmen M,et al.Quantitative MRI of the hippocampus and amygdale in severe depression.Psychological Medicine,2000,30(1):117-125.
7.Andrew LS,Perry FR,Deborah AYT,et al.Neuroimaging in bipolar disorder:what have we learned?Society of Biological Psychiatry,2000,48(6):505-517.
8.夏军,周义成,张景峰.抑郁症患者海马及杏仁核容积异常的 MRI 研究[J].中华放射学杂志.2005;39(2):140-143.
9.Coffey CE,Wilkinson WE,Weiuer RD,et al.Quantitative cerebral anatomy in depression.A controlled magnetic resonance imaging study.Archives of General Psychiatry,1993;50(1):7-16
10.Krishnan KR,McDonald WM,Doraiswamy PM,et al.Neuroanatomical substrates of depression in the elderly.Eur Arch Psychiatry Clin Neurosci,1993;243(1):41-46.
11.Figiel GS,Coffey CE,Weiner RD.Brain Magnetic Resonance Imaging in Elderly Depressed Patients Receiving Electroconvulsive Therapy.Convuls Ther,1989;5(1):26-34.
12.Husain MM,Figiel GS,Lurie SN,et al.MRI of corpus callosum and septum pellucidum in depression.Biol Psychiatry,1991,29(3):300-301.
13.Altshuler LL,Conrad A,Hauser P,et al.Reduction of temporal lobe volume in bipolar disorder:a preliminary report of magnetic resonance imaging.Arch Gen Psychiatry,1991,48(5):482-3.
14.卢广,胡红兵,丁广良,等.大白鼠抑郁症模型的 MRI 方法研究[J].波谱学参 考 文 献杂志.1998;15(4):303-306.
15.王雪琦,路长林,李丽云,等。大鼠抑郁模型的脑磁共振成像研究[J].中华精神科杂志,1999,32(1):12-14.
16.Nauta WJ. Neural associations of the frontal cortex. Acta Neurobiol Exp(Warsz) ,1972,32:125- 140.
17.Sheline Y. 3D MRI stuies of neuroanatomic changes in unipolar major depression: The role of stress and medical comorbidity. Biol Psychiatry, 2000,48:791- 800.
18.Degl Innocenti A, Agren H, Backman l. Executive deficits in major depression.Acta Psychiatr Scand,1998,97:182-188.
19.Dougherty D, Rauch SL1 Neuroimaging and neurobiological models of dep ression1 Harv Rev Psychiatry, 1997, 5: 138-159.
20.Rajkowska G, Miguel2Hidalgo JJ, Wei J, et al1 Morphometric evidence for neuronal and glial prefrontal cell pathology in major dep ression1 Biol Psychiatry, 1999, 45: 1085-1098.
21.牟君,谢鹏,杨泽松,等。初发抑郁症患者丘脑质子磁共振波谱分析[J].中国神经精神疾病杂志,2007,33(4)229-232.
22.Geurts JJ, Barkhof F, Castelijns JA, et al. Quantitative 1H-MRS of healthy human cortex, hippocampus, and thalamus: metabolite concentrations, quantification p recision, and reproducibility. J Magn Reson maging, 2004,20(3):366.
23.Vythilingam M, Charles HC, Tupler LA , et al. Focal and lateralized subcortical abnormalities in unipolar major depressive disorder: an automated multivoxel proton magnetic resonance spectroscopy study. Biol Psychiatry, 2003, 54 (7) : 744.
24.Gruber S, Frey R, Mlynarik V, et al. Quantification of metabolic differences in the frontal brain of depressive patients and controls obtained by 1H-MRS at 3 Tesla. Invest Radiol, 2003, 38 (7):403.
25.Yildiz-Yesiloglu A, Ankerst DP. Review of 1H magnetic resonance spectroscopy findings in major depressive disorder: a meta-analysis.Psychiatry Res, 2006, 147(1) : 1.
26.Young KA, Holcomb LA, Yazdani U, et al. Elevated Neuron Num-ber in the Limbic Thalamus in Major Depression. Am J Psychiatry,2004, 161 (7) : 1270.
27.林铮,李惠春,等。抑郁症患者前额叶、海马磁共振质子波谱成像的研究[J].中华精神科杂志,2005, 38(4):193-197.
28.Kato T, Inubushi T, Kato N. Magnetic resonance spectroscopy in affective disorders J Neurop sychiatry Clin Neurosci, 1998, 10: 133-147.
29.Jung RE, Brooks WM, Yeo RA, et al. Biochemical markers of intelligence: a protonMR spectroscopy study of normal human brain.Proc Biol Sci, 1999, 266: 1375-1379.
30.Miller BL, Chang L, Booth R, et al. In vivo 1H-MRS choline:correlation with in vitro chemistry/histology. Life Sci, 1996, 58:1929-1935.
31.Gup ta RK, Bhatia V, Poptani H, et al. Brain metabolite changes on in vivo proton magnetic resonance spectroscopy in children with congenital hypothyroidism1 J Pediatr, 1995, 126: 389-392.
32.Bustillo JR, Rowland LM, Lauriello J, et al. High choline concentrations in the caudate nucleus in antip sychotic-naive patients with schizophrenia1.Am J Psychiatry, 2002, 159: 130-133.
33.Navarro V, Gasto C, Lomena F, et al. Frontal cerebral perfusion after antidepressant drug treatment versus ECT in elderly patients with major depression: a 12-month follow-up control study. J Clin Psychiatry, 2004, 65: 656-661.
34.Videbech P. PET measurements of brain glucose metabolism and blood flow in major dep ressive disorder: a critical review. Acta Psychiatr Scand, 2000, 101: 11-20.
34.Kumar A, Thomas A, Lavretsky H, et al. Frontal white matter biochemical abnormalities in late-life major depression detected with proton magnetic resonance spectroscopy. Am J Psychiatry, 2002,159: 630-636.
35.Bell-McGinty S, Butters MA, Meltzer CC,et al. Brain morphometric abnormalities in geriatric depression: Longterm neurobiological effects of illness uation. Am J Psychiatry ,2002,159:1424-1427.
36.Bremner JD, Narayan M, Anderson ER, et al. Hippocampal volume reduction in major depression. Am J Psychiatry,2002, 157:115-118.
37.MacQueen GM, Campbell S, McEwen B, et al. Course of illness, hippocampal function and volume in major depression.Proc Natl Acad Sci U S A, 2003,100:1387-1392.
38.Sheline Y, Sanghavi M, Mintun M, et al. Depression duration but not age predicts hippocampal volume loss in women with recurrent major depression. J Neurosci ,1999,19:5034- 5043.
39.Sheline Y, Sanghavi M, Mintun M, et al. Depression duration but not age predicts hippocampal volume loss in women with recurrent major depression. J Neurosci ,1999, 19:5034-5043.
40.Vakili K, Pillay SS, Lafer B, et al. Hippocampal Volume in primary unipolar major depression: A magnetic resonance imaging study. Biol Psychiatry ,2000, 47:1087-1090.
41.Bowley MP, Drevets WC, Ongur D, et al. Low glial numbers in the amygdala in major depressive disorder. Biol Psychiatry ,2002, 52:404- 412.
42.Frodi T, Mesienzahl E, Zetzsche T, et al. Hippocampal changes in patients with a first episode of major depression.Am J Psychiatry ,2002,159:1112-1118.
43.Steffens DC, Byrum CE, Mcquoid DR ,et al. Hippocampal volume in geriatric depression .Biol Psychiatry ,2000,48:301-309.
44.Stephanie Campbell, Michael Marriott, Claude Nahmias, et al. Lower Hippocampal Volume in Patients Suffering From Depression: A Meta- Analysis ,2004,161:598-607.
45.Mervaala E, Fohr J, Kononen M, et al. Quantitative MRI of the hippocampus and amygdala in severe depression1 Psychol Med,2000, 30: 117-125.
46.Von Gunten A,Fox NC, Cipolotti L, et al. A volumetric study of hippocampus and amygdala in depressed patients with subjective memory problems.J Neuropsychiatry clin Neurosci ,2000,12:493-498
47.Sheline YI, Gado MH, Price JL. Amygdala core nuclei volumes are decreased in recurrent major dpression.Neuroreport, 1998,9:2023- 2028.
48.Mervaala E, Fohr J, Kononen M, et al. Quantitative MRI of the hippocamjpus and amygdala in severe depression.Psychol Med, 2000, 30:117- 125.
49.Frodl T, Meisenzahl E,Zetzsche T, et al .Enlargement of the amygdala in patients with a first episode of major depression. Biol Psychiatry, 2002,51:708- 714.
50.AshtariM, Greenwald BS, Kramer-Ginsberg E, et al. Hippocampal/amygdalavolumes in geriatric depression.Psychol Med ,1999, 29:629- 638.
51.Sapllsky RM Glucocorticoids and hippocamal atrophy in neuropsychiatric disorders. Arch Gen Psychiatry, 2000, 57: 925- 935.
53.Bourdeau I, Brad C, Noel B, et al. Loss of brain volume in endogenous Cushing's syndrome and its reversibility after correction of hypercortisolism. J Clin Endocrinol Metab,2002,87:1949-1954.
53.Carmichael ST, Price JL . Limbic connections of the orbital and medial prefrontal cortex in macaque monkeys. J Comp Neurol ,1995,363:615- 641.
54.Gould E, McEwen BS, Tanapat P, et al. Neurogenesis in the dentate gyrus of the adult tree shrew is reglated by psychosocial stress and NMDA receptor activation. J Neurosci ,1997,17:2492- 2498.
55.Alexopoulos GS, Kiosses DN, Choi SJ, et al. Frontal white matter microstructure and treatment response of late – life depression: A preliminary study. Am J Psychiatry,2002,159:1929- 1932.
1.中华医学会精神科分会主编.中国精神障碍分类与诊断标准[M]. 第三版. 济南. 山东科学技术出版社,2001:87～88.
2.汪向东.心理卫生评定量表手册[M].增订版,北京:中国心理卫生出版社,1999:220～223.
3.张捷,裴音,孙静.以针灸为主治疗抑郁症诊疗模式初探[J].北京中医,2007, 26 (3 ):137～139.
4.方向东, 蔡信诚.针药并用治疗抑郁症 52 例疗效观察[J].上海针灸杂志,2007, 26(2):19～20.
5.卢峻,时宇静,图娅. 不同频率电针对模型大鼠抗抑郁效应的比较研究. 北京中医药大学学报,2003,26(6):83-84.
6.Cheung F M. Psychological symptoms among Chinese in urban Hong Kong[J] . Social Science and Medicine ,1982,16(14):1339～1344.
7.孙华,张有志,韩毳. 电针对慢性应激抑郁模型大鼠大脑皮层 5-HT1和 5-HT2受体数量和结合性的影响[ J ]. 中国针灸, 2003,23 (9):553～554.
8.邱艳明,时宇静,图娅. 电针印堂、百会对获得性无助大鼠不同脑区内单胺类神经递质的影响. 北京中医药大学学报,2002 ,25(6):54-56.
9.李文迅,韩焱晶,陶娟,等. 电针对抑郁模型大鼠海马神经元凋亡的影响. 中国中医药信息杂志,2005,12(2):33-35.
10.淑莎尼克,图娅.电针与百优解对照治疗抑郁症的临床观察.针刺研究,2006,31(4):242-243.
11.卢峻,韩止荣,时宇静,等.电针治疗抑郁症近 10 年研究进展.针刺研究,2005,30(1):56-59.
1.Tadafumi K, Toshiro I, Nobumasa K, et al. Magnetic resonance spectroscopy in affective disorder. Journal of Neuropsychiatry and Clinical Neurosciences. 1998;10(2):133 一147.
2.侯钢,张心保,陈钰等.抑郁症患者中枢单胺类神经递质相互关系的对照研究.中国神经精神疾病杂志.2002; 28(1): 7-8.
3.郭珊,郭克锋.抑郁症的研究进展.中国临床康复.2005; 9(4): 131-133.
4. Campbell S, Maqueen G. The role of the hippocampus in the pathophysiology of major depression. J Psychiatry Neurosci. 2004; 29 (6): 417-426.
5. Hashimoto K, Shimizu E, Iyo M. Critical role of brain-derived neurotrophic factor in mood disorders. Brain Res Rev. 2004; 45 (2): 104-114.
6. Reichelt KL, Kvamme E. Histamine-dependent formation of N-acetyl-aspartyl peptides in mouse brain. J Neurochem. 1973; 21:849-859.
7. McIntosh JC, Cooper JR.Studies in the function of-acetylaspartic acid in brain. J Neurochem, 1965; 12: 825-835.
8. Simmons ML, Frondoza CG,Coyle JT. Immunocytochemical localization of N-acetyl-aspartate with monoclonal antibodies. Neuroscience. 1991;45:37-45.
9. D'Adamo AF, Gidez LI Yatsu FM. Acetyl transport mechanisms. Involvement of N-acetyl aspartic acid in de novo fatty acid biosynthesis in the developing rat brain. Exp Brain Res. 1968; 5: 267-273.
10.Shigematsu H, Okamura N, Shimeno H, et al. Purification and characterization of the heat-stable factors essential for the conversion of lignoceric acid to cerebronic acid and glutamic acid: identification of N-acetyl-L-aspartic acid. J Neurochem. 1983; 40: 814-820.
11.Sabatier J, Gilard V, Malet-Martino M, et al. Characterisation of choline compounds with in vitro 1H magnetic resonance spectroscopy for discrimination of primary brain tumours. Invest Radiol. 1999; 34: 230-235.
12.Brooks WM, Friedman SD, Stidley CA. Reproducibility of 1H MRS in vivo. Magn Reson Med.1999; 41(1): 193-197.
13.Miller BL. A review of chemical issues in 1HNMR spectroscopy: acetylaspartate, creatine and choline. NMR Bio med. 1991;4: 47-52.
14.谢长青,卢曼丽,吴光耀.脑组织质子磁共振波谱成像.武汉大学学报(医学版).2003; 24(4): 366-369.
15.Pouwels PJ, Frahm J. Regional metabolite concentrations in human brain as determined by quantitative localized proton MRS. Magn Reson Med. 1998; 39: 53-60.
16.Frahm J, Bruhn H, Gyngell ML, et al. Localized proton NMR spectroscopy in different regions of the human brain in vivo: relaxation times and concentrations of cerebral metabolites. Magn Reson Med. 1989; 11:47-63.
17.Manton DJ, Lowry M, Blackband SJ, et al. Determination of proton metabolite concentrations and relaxation parameters in normal human brain and intracranial tumors. NMR Biomed. 1995; 8: 104-112.
18.Dawn E, Saunders, Franklyn A, et al. Aging of the adult human brain: in vivo quantitation of metabolite content with proton magnetic resonance spectroscopy.MRI. 1999; 5: 711-716.
19.Petra SH. MR imaging and spectroscopy of brain development. MRI Clin North Am .2001;9(1): 1-17.
20.范国光,吴振华,刘芳,等.我国正常成人脑 1H 磁共振波谱的定量研究.中国医学影像技术.2000; 16(7): 535-538.
21.Kimbrell TA, Ketter TA, George MS, et al. Regional cerebral glucose utilization in patients with a range of severities of unipolar depression. Biol Psychiatry. 2002; 51(3):237-252.
22.Brody AL, Saxena S, Silverman DHS, et al. Brain metabolic changes in major depressive disorder from pre- to post-treatment with paroxetine. Psychiatry Res Neuroimaging. 1999; 1:127-139.
23.Jeffrey AS. In Vivo magnetic resonance spectroscopy and its application to neuropsychiatric disorders. Can J Psychiatry. 2002; 47: 315-326.
24.王祖新.抑郁症的病因学研究.中华内科杂志.1998; 37(8): 568.
25.周旋,王雪琦.谷氨酸能和γ氨基酸能系统与情感障碍.中国神经科学杂志. 2003;19(2): 130-133.
26.Moghaddam B, Adams BW. Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science. 1998; 281:1349-1352.
27.Sanacora G, Mason GF, Rothman DL, et al. Reduced cortical GABA levels in depressed patients determined by 1H-magnetic resonance spectroscopy. Arch Gen Psychiat. 1999; 56: 1043-1047.
28.Rubin RT, Phillips JJ, McCracken JT, et al. Adrenal gland column in major depression relationship to basal and stimulated pituitary-adrenal cortical axis function. Biological Psychiatry. 1996; 40(2): 89-97.
29. Duman RS, Malberg J, Nakagawa S. Neuronal plasticity and survival in mood disorders. Biol Psychiatry. 2000; 48:732-739.
30.Soares JC, Mann JJ. The anatomy of mood disorders-review of structural neuroimaging studies. Biol Psychiatry. 1997; 41:86-106.
31 Sheline YI, Mittler BL, Mintun MA. The hippocampus and depression. European Psytchiatry. 2002; 17(Supplement3): 300-305.
32.Coffey CE, Wilkinson WE, Weiner RD, et al. Quantitative cerebral anatomy in depression. A controlled magnetic resonance imaging study. Archives of General Psychiatry. 1993; 50(1):7-16.
33.Rajkowska G, Miguel-Hidalgo JJ, Wei J, et al. Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression. Biol Psychiatry. 1999; 45(9):1085 一1098.
34.Thomas F, Eva MM, Thomas Z, et al. Hippocampal changes in patients with a first episode of major depression. Am J Psychiatry. 2002; 159(7): 1112-1118.
35.Mervavla E, Folhr J, Kononen M, et al. Quantitative MRI of the hippocampus and amygdala in severe depression. Psychological Medicine. 2000; 30(1):117-125.
36.Steffens DC, Byrum CE, McQuoid DR et al. Hippocampal volume in geriatric depression. Biol Psychiat. 2000; 48: 301-309.
37.夏军,陈军,周义成,等.抑郁症患者边缘系统异常的MRI 和MRS分析.中国医学影像技术.2004; 20(6): 856-859.
38.赵晋华.抑郁症的放射性核素脑血流灌注和脑受体显像研究进展.国外医学放射医学核医学分册.1998; 22(2): 49-51.
39. Delvenne V, Goldman S, Biver F, et al. Brain hypometabolism of glucose in low weight depressed patients and in anorectic patients: a consequence of stavation? J Affective Disorders. 1997; 44: 69-77.
40.苗群,施慎逊,王占伟.功能性影像技术在抑郁症研究中的进展.中华精神科杂志.1999; 32(1): 57-59.
41. Blumberg HP, Leung HC, Wexler B, et al. Ventral prefrontal dysfunction in bipolar disorder: an fMRI study. Biol Psychiatry. 2001;49: 26.
42. Kennedy SH, Evans KR, Kruger S, et al. Changes in regional brain glucose metabolism measured with positron emission tomography after paroxetine treatment of major depression. Am J Psychiatry. 2001;158(6): 899-905.
43.Drevets WC, Price JL, Simpson JR, et al. Subgenual prefrontal cortex abnormalities in mood disorders. Nature. 1997; 386: 824-827.
44.Magaris AM, Deslandes A, Mcewen BS. Effect of antidepressant and benzodiazepine trentments on the dendritic structure of CA3 pyrimidal neurons after chronic stress. Eur J Pharmacol. 1999; 371(23):113-122.
45.Rajkowska G. Cell pathology in bipolar disorder. Bipolar Disord. 2002; 4: 105-116.
46.徐丹令,李广君,倪之挺.谷氨酸对大鼠海马兴奋毒性作用的形态学研究.解 剖学杂志.2001; 24(1): 25-27.
47. Cecil KM, DelBello MP, Morey R, et al. Frontal lobe differences in bipolar disorder as determined by proton MR spectroscopy. Bipolar Disord. 2002; 4: 357-365.
48. Winsberg ME, Sachs N, Tate DL, et al. Decreased dorsolateral prefrontal N-acetyl aspartate in bipolar disorder. Biol Psychiatry. 2000; 47: 475-481.
49.王雪琦,卢广,孙学军,等.大鼠抑郁症模型脑磁共振成像和波谱研究.中国 神经科学杂志.1999; I5(2): 162-165.
50. Tapiero H, Mathe G, Couvreur P, et al. Free amino acids in human heath andpathologies II .Glutamine and glutamate. Bio Pharmacother. 2002; 56: 446-457.
51.Steingard RJ, Yurgelun-Todd DA, Hennen J, Moore JC,et al. Increased orbitofrontal cortex levels of choline in depressed adolescents as detected by in vivo proton magnetic resonance spectroscopy. Biol Psychiatry. 2000; 48: 1053-1061.
52. Ongur D, Drevets WC, Price JL. Glial reduction in the subgenual prefrontal cortex in mood disorders. Proc Natl Acad Sci USA. 1998; 95: 13290-13295.
53. Bowley MP,Drevet WC, Ongur D. Low glial numbers in the amygdale in major depressive disorder. Biol Psychiatry. 2002; 52(5): 404-412.
54. Kato T, Hamakawa H, Shioiri T, et al. Cholinecontaining compounds detected by proton magnetic resonance spectroscopy in the basal ganglia in bipolar disorder. J Psychiatry Neurosci. 1996; 21:248-254.
55.Kumar A, Thomas A, Lavretsky H, et al. Frontal white matter biochemical abnormalities in late-life major depression detected with proton magnetic resonance spectroscopy. Am J Psychiatry. 2002; 159(4): 630-636.
56.Farchione TR,Moore GJ, Rosenberg DR. Proton magnetic resonance spectroscopic imaging in pediatric major depression. Biol Psychiatry. 2002;15;52(2): 86-92.
57.林铮,李惠春,龚向阳,等.抑郁症患者前额叶、海马磁共振质子波谱成像的研究.中华精神科杂志.2005; 38(4): 193-197.
58.Taylor W, James R, Macfall, et al. Late-life depression and micro structural abnormalities in dorsolateral prefrontal cortex white matter. Am J Psychiatry. 2004; 161(7): 1293-1296.
59.Gruber S, Frey R, Mlynarik V, Stadlbauer A, et al. Quantification of metabolic differences in the frontal brain of depressive patients and controls obtained by 1H-MRS at 3 Tesla. Invest Radiol. 2003; 38(7): 403-408. ? ? ?
1.李文迅,图娅,方芳,等. 电针对抑郁模型大鼠脑形态结构影响的磁共振成像研究. 中华物理医学与康复杂志. 2005,27(4):214-217.
2.李文迅,韩焱晶,陶娟, 等. 电针对抑郁模型大鼠海马神经元凋亡的影响. 中国中医药信息杂志,2005,12(2):33-35
3.卢峻,韩止荣,时宇静,等. 电针治疗抑郁症近 10 年研究进展. 针刺研究,2005,30(1):56-59
4.卢峻,时宇静,费宇彤,等. 电针对抑郁症模型大鼠磷酸化cAMP 反应元件结合蛋白表达的影响. 中国中医基础医学杂志,2006,12(5):380-382
5.邱艳明,时宇静,图娅. 电针印堂、百会对获得性无助大鼠不同脑区内单胺类神经递质的影响. 北京中医药大学学报,2002 ,25(6) :54-56
6.Kleinman A. 美国精神病学界关于抑郁症、躯体化障碍及神经衰弱的近代观点[J]. 国外医学精神病学分册,1980,4:212-216.
7. Cheung FM. Psychological symptoms among Chinese in urban Hong Kong[J]. Soc Science Med,1982,16:415-422.
8. 徐俊冕,张琳,江开达,等. 焦虑和抑郁的躯体化[J]. 上海精神医学,1991,3 :6-10.
9.姚道元,龚震命. 综合性医院中抑郁症及其躯体化症状的研究[J]. 四川精神卫生,1998,11:85-87.
2.赵志升,赵敏.抑虑康治疗郁证 180 例疗效观察.山东中医杂志,1999, 18 (3):110-112.
3.刘宝录.解郁汤治疗隐匿性抑郁症31 例体会.天津中医,1999, 8 (1):16-18.
4.赵嘉萍.解郁汤治疗抑郁症.四川中医,1992, 10 (8): 35-36.
5.郭雅明,刘翠峰.王彦恒治疗抑郁症经验.河北中医,2002, 24 (2):100-101.
6.陈日宙.忧郁证从脾肾论治.光明中医杂志,1995, 10 (6): 7-8.
7.胡思荣.平心忘忧汤治疗抑郁症470 例.湖北中医杂志,1996, 18 (2):4-5.
8.郝万山.柴桂温胆定志汤为主治疗精神抑郁症.北京中医药大学学报,1997, 20 (3):64-65.
9.刘兰英.“脑为元神之府”理论在针灸治疗抑郁症中的指导意义.针灸临床杂志,2003, 19 (8):6-9.
10.全世建.百合地黄汤加减治疗抑郁症30 例疗效观察.新中医,1999, 31(2):16-17.
11.陈珠娇.中医治疗老年性抑郁症22 例.福建中医药1998, 29 (6): 22.
12.曲森,唐启盛.抑郁症与中医“郁证”的关系探讨.北京中医药大学学报,2004, 27 (1):11-13.
13. 张泰康.谈老年妇女精神抑郁症的辨治[J].山东中医药杂志1989;8(4):4-6.
14. 张兰柱.浅谈更年期抑郁症的辨证治疗[J].中国中医基础医学杂志 2001;7(7):533-535.
15. 李金瑚.老年期抑郁症从肾论治[J].新中医1990;22(5):54-56.
16. 郝万山,柴桂.温胆定志汤为主治疗精神抑郁[J].北京中医药大学学报 1997;20(3):64-66.
17. 武志平,闫桂玲.自拟补源解郁汤治疗妇女忧郁症 156 例[J].中国民间疗法 1998;10(5):48-50.
18. 许沛虎.中医脑病学.北京:中国医药科技出版社,1998:925-927.
19. 骆方.大钟穴的临床应用[J].浙江中医学院学报,1992,(3):50-52.
20. 刘志顺,刘军,黄漫,等.调理髓海法治疗中风后抑郁症 30 例临床观察[J].中国针灸,1997,(9):543-544.
21.刘志顺,黄石玺,黄漫,等.针刺治疗中风后抑郁症临床研究[J].实用中西医结合杂志,1997,10(11):1038-1039.
22.李建生,张杰,杨戈.中医药治疗老年抑郁症的研究概况[J].河南中医药学刊,2001,16(1):10-13.
23.姜凤莲,马建功.针刺治疗老年期抑郁症[J].河北中医,1997,17(6):373-375.
24.叶国传.针刺治疗抑郁症36 例[J].上海针灸杂志,2000,(6):30-32.
25.费宇彤,杨德强,时宇静,等.近 10 年国际针刺临床文献分析.中国中医药信息杂志,2006,13(4):101-102.
26.蒋振亚,何玲娜,彭力群,等.针刺天谷八阵治疗中风后抑郁症[J].中国针灸,2002,22(1):30-32.
27.费宇彤,杨德强,焦爽,等.近 10 年国际针刺临床病种变化研究.中国中医药信息杂志,2006,13(5):102-103.
28.杨敏,陈晓莉.针灸治疗抑郁症的近况[J].浙江中医杂志,2002,(3):128-129.
27.丁德正.精神病抑郁状态辨治体会[J].陕西中医,1994,(4):191- 192.
28.罗和春.抑郁症的电针合并舒血宁治疗与实验室细胞免疫水平改变的研究[J].美国中华健康卫生杂志,2000,3(2):1-3.
29.马静.针灸治疗抑郁症的临床研究[J].中华现代临床医学杂志,2005; 3 (11):1094-1095.
30.符文彬.针灸对抑郁性神经症的治疗作用[J].中国临床康复,2002; 6 ( 5 ): 679.
31.黄学军,罗仁浩.针刺治疗抑郁性神经症疼痛的疗效[J].广东医学,2000; 20 (8)704.
32.张春红,李金波,王舒.在德国运用“醒脑开窍针刺法”治疗郁证的临床观察[J].针灸临床杂志,2002; 18 (8): 26.
33.刘志顺.调理髓海法治疗中风后抑郁症 30 例临床观察[J].中国针灸,1997; 21(4):200.
34.张中发,王军峰,杜贵平.电针百会印堂穴在精神科的应用[J].中国针灸,2001,(10):633-636.
35.罗和春,沈渔邨,贾云奎.电针治疗 133 例抑郁症患者临床疗效观察[J].中西医结合杂志,1988,(2):77-80.
36.刘广志,贾云桂,詹丽,等.电针治疗早老期,老年期抑郁状态的临床疗效观察[J].中医杂志,1991,(5):36-38.
37.王辉,于恩庆,赵军,等.电针治疗 129 例精神科常见病疗效分析[J].针灸临床杂志,1999,(l):42-44.
38.陈光,周东丰,沈渔村,等.抑郁病人TRH 兴奋试验及实验结果与DST尿MHPG·SO4排出量的关系[J].中华神经精神科杂志;1991,24(4):203-205.
39.周东丰.精神疾病的神经生化基础和电针治疗抑郁症的机理研究[J].电针治疗抑郁症及有关中西医综合新技术资料汇编.北京医科大学精神卫生研究所,1992.18-20.
40.林虹.电针治疗产后精神障碍抑郁型53 例疗效观察[J].天津中医,1996,(2):4-6.
41.侯冬芬,罗和春.电针百会印堂治疗30 例中风后抑郁患者临床疗效观察[J].中国针灸,1996,(8):23-24.
42.杨坤英.电针百会印堂穴治疗抑郁症临床观察[J].天津中医,1998,15(6):124-125.
43.董子平.电针治疗抑郁症101 例[J].中国针灸,2001,(1):6-8.
44.淑莎尼克,图娅.电针与百优解对照治疗抑郁症的临床观察.针刺研究,2006,31(4):242-243.
45.淑莎尼克,图娅.针灸与百优解对照治疗抑郁症的临床研究.中华中西医杂志,2006,7(11):961-964.
46.赵秀敏.背俞穴穴位注射配合针刺治疗郁证[J].中国中医药信息杂志,2001; 8 (12):78.
47.李振芝,洗莉,讳晓晴等.针刺配合离子导入治疗抑郁性神经症258 例临床观察[J].中国针灸,1998; 21(8) : 465.
48.任建宁.耳针治疗抑郁症50 例[J].河南中医,2005; 25 (2 ): 75.
49.秦丽娜,史榕荇.电针对慢性应激抑郁模型大鼠脑肠肽类激素的影响[J].安徽中医学院学报,2007;(1):26.
50.高碧霄.十余年来百会穴研究概况[J].中医文献杂志,1997; (2):41-43.
51.段方胜,吴钢,郑依勇等.针刺四关穴对头痛患者脑血流动力学的影响[J].上海针灸杂志,1996; 15 (2):5.
52.徐虹,孙忠人,李丽萍,等.针刺治疗抑郁症及其对患者下丘脑一垂体一肾上腺轴的影响[J].中国针灸,2004; 24(2): 78.
53.杜元灏,李桂平,颜红,等.调神疏肝针法治疗郁症的临床研究[J].中国针灸,2005;25 (3):151.
54.金光亮,周东丰,苏晶.电针对慢反应应激抑郁模型大鼠单胺类神经递质的影响[J].中国精神科杂志,1999,32(4):220-222.
55.韩毳,李晓泓,李学武,等.电针“百会”、“三阴交”穴对慢性应激抑郁模型大鼠 HPA轴的影响[J].北京中医药大学学报,2001,24(3):74-76.
56.邱艳明,时宇静.电针印堂、百会对获得性无助大鼠不同脑区内单胺类神经递质的影响[J].北京中医药大学学报,2002,25(6):54-56.
57.韩毳,王磊,等.电针对抑郁症患者血清细胞因子的影响[J].中国行为医学科学,2002,11(3)277-279.
58.黄泳,唐安戊,李求实,等.运用 PET 技术研究头电针治疗抑郁症的机理[J].四川中医,2004;22(10):6.
59.俞瑾,李晓艳,曹小定,等.电针合用抗抑郁药能明显减少小鼠强迫游泳实验中的静止时间[J].针刺研究,2002,27(2):119-123.
60.孙华,张有志.针灸百会和足三里穴对抑郁模型小鼠和大鼠行为的影响[J].针灸临床杂志,2003,19(2):47-49.
61.韩毳,李学武,李晓泓,等.电针对慢性应激抑郁模型大鼠海马BDNF 的影响[J].中国中医基础医学杂志,2001,7(7):55-57.29.
1. 江开达,江三多,王红霞等.单相抑郁症中 5-HT2A 受体基因及 MAOA 型基因的相互影响.中国神经精神疾病杂志,1999; 25 (2) :90-92.
2. 王立伟,江三多,汪栋祥等.5-羟色胺6 受体基因多态性与抑郁症的关联研究.中华精神科杂志,2000;33(4):216-217.
3. Van Wi·Jngaarden M Th M,Tulp W Soudijn,The concept of selectivity in 5-HT receptor research,European Journal of Pharmacology- Molecular Pharmacology Section,1990,188:301-312.
4. Zemlan FP,Garver DL.Depression and antide pressant therapy:receptor dynamics [J].Prog Neuropsychopharmacol Biol Psychiatry, 1990,14(4): 503-523.
5. Ehlers CL, Somes C, Seifritz E, et al. CRF/NPY interactions:a potential role in sleep dysregulation in depression and anxiety. Depress Anxiety 1997 6(1):1-9.
6. Antonijevic IA, Murck H, Bohlhalter S, et al. Neuropeptide Y promotes sleep and inhibits ACTH and cortisol release in young men. Neuropharmacology 2000, 39(8):1474-81.
7. Sapolsky RM . Glucocorticoids and hippocampal atrophy in neuropsychiatric disorders . Arch Gen Psychiatry,2000,57:925-935.
8. Paskitti ME , McCreary BJ , Herman JP.Stress regulation of adrenocorticosteroid receptor gene transcription and mRNA expression in rat hippocampus:time-course analysis.Brain Res Mol Brain Res,2000,80:142-152.
9. Lucassen PJ, Muller MB, Holsboer F,et al. Hippocampal apoptosis in major depression is a minor event and absent from subareas at risk for glucocorticoid overexposure.Am J Pathol, 2001,158 :453-468.
10. Zahorodna A,Tokarski K,Bijak M . Electrophysiologic tests for testing the effects of antidepressant drugs and corticosterone on reactivity of serotonin receptors in the hippocampus.Postepy Hig Med Dosw,2000,54:391-401.
11. Frank MG,Hendricks SE,Bessette D.Levels of monocyte reactive oxygen species are associated with reduced natural killer cell activity inmajor depressive disorder.Neuropsychobiology 2001,44(1):1-6.
12. Mizoguchi K,Yuzurihara M,Ishige A,et al.Chronic stress differentially regulates glucocorticoid negative feedback response in rats. Psychoneuroendocrinology,2001,26: 443-459.
13. Peteranderl C, Antonijevic IA, Steiger A, et al. Nocturnal secretion of TSH and ACTH in male patients with depression and healthy controls. J Psychiatr Res 2002, 36(3):189-96.
14. Lloyd RL, Pekary AE, Sattin A, et al. Antidepressant effects of thyrotropin –releasing hormone analogues using a rodent model of depression. Pharmacol Biochem Behav 2001,70(1):15-22.
15.孙士友,舒良,白惠卿等.抑郁症患者细胞免疫功能的研究.中华精神科杂志1998;31(1):23-25.
16. MaddockC,ParianteCM.How dose stress affect you? An overview of stress, immunity, depression and disease.Epidemiol Psychiatr Soc,2001 Jul-Sep,10(3):153-156.
17. Toussaint M, Luthringer R, Staner L, etal.Channges in EEG power density during sleep laboratory adaptation in depressed in patients. BiolPsychiatry, 2000,47:626-633.
18.张心保,侯钢,耿直等.抑郁症及其亚型的睡眠脑电图研究.中华精神科杂志,1999,32(1): 30.
19.Shagass C. Age, personality and somatosensory cerebral evoked responses. Science, 1965, 148:1359-1364.
20.Spehiman R. VEP, AEP and SEP in Clinical Diagnosis. Battrwith Heineman,l985:89-94.
21.林明方,李建军.抑郁症首次发病患者额叶三维磁共振氢质子波分析研究[J]. 中华精神科杂志, 2006 ,1:5-8.
1.林平尔.磁共振在精神医学研究中的应用[J].国外医学精神病学分册.1994.21(4):231-233.
2.崔青,彭昌孝,刘文.抑郁症患者脑的磁共振研究[J].临床精神医学杂志.2001.11(6):344-345.
3.Soares JC,Krishnan KR,Keshavan MS.Nuclear magnetic resonanc espectroscopy : new insights in to the pathophysiology of mood disorders.Depression 1996;4:14.
4.Drevets WC,Price JL,Simpson JK,et al.Subgenual prefrontal cortex abnormalities in mood disorders.Nature 1997;27:824.
5.Sheline YI,Wang PW,Gado MH,et al.Hippocampal atrophy in recurrent major depression.Proc Natl Acad Sci 1996;93(9):3908-3913.
6.Mervaala E,Folhr J,Kgngmen M,et al.Quantitative MRI of the hippocampus and amygdale in severe depression.Psychological Medicine,2000,30(1):117-125.
7.Andrew LS,Perry FR,Deborah AYT,et al.Neuroimaging in bipolar disorder:what have we learned?Society of Biological Psychiatry,2000,48(6):505-517.
8.夏军,周义成,张景峰.抑郁症患者海马及杏仁核容积异常的 MRI 研究[J].中华放射学杂志.2005;39(2):140-143.
9.Coffey CE,Wilkinson WE,Weiuer RD,et al.Quantitative cerebral anatomy in depression.A controlled magnetic resonance imaging study.Archives of General Psychiatry,1993;50(1):7-16
10.Krishnan KR,McDonald WM,Doraiswamy PM,et al.Neuroanatomical substrates of depression in the elderly.Eur Arch Psychiatry Clin Neurosci,1993;243(1):41-46.
11.Figiel GS,Coffey CE,Weiner RD.Brain Magnetic Resonance Imaging in Elderly Depressed Patients Receiving Electroconvulsive Therapy.Convuls Ther,1989;5(1):26-34.
12.Husain MM,Figiel GS,Lurie SN,et al.MRI of corpus callosum and septum pellucidum in depression.Biol Psychiatry,1991,29(3):300-301.
13.Altshuler LL,Conrad A,Hauser P,et al.Reduction of temporal lobe volume in bipolar disorder:a preliminary report of magnetic resonance imaging.Arch Gen Psychiatry,1991,48(5):482-3.
14.卢广,胡红兵,丁广良,等.大白鼠抑郁症模型的 MRI 方法研究[J].波谱学参 考 文 献杂志.1998;15(4):303-306.
15.王雪琦,路长林,李丽云,等。大鼠抑郁模型的脑磁共振成像研究[J].中华精神科杂志,1999,32(1):12-14.
16.Nauta WJ. Neural associations of the frontal cortex. Acta Neurobiol Exp(Warsz) ,1972,32:125- 140.
17.Sheline Y. 3D MRI stuies of neuroanatomic changes in unipolar major depression: The role of stress and medical comorbidity. Biol Psychiatry, 2000,48:791- 800.
18.Degl Innocenti A, Agren H, Backman l. Executive deficits in major depression.Acta Psychiatr Scand,1998,97:182-188.
19.Dougherty D, Rauch SL1 Neuroimaging and neurobiological models of dep ression1 Harv Rev Psychiatry, 1997, 5: 138-159.
20.Rajkowska G, Miguel2Hidalgo JJ, Wei J, et al1 Morphometric evidence for neuronal and glial prefrontal cell pathology in major dep ression1 Biol Psychiatry, 1999, 45: 1085-1098.
21.牟君,谢鹏,杨泽松,等。初发抑郁症患者丘脑质子磁共振波谱分析[J].中国神经精神疾病杂志,2007,33(4)229-232.
22.Geurts JJ, Barkhof F, Castelijns JA, et al. Quantitative 1H-MRS of healthy human cortex, hippocampus, and thalamus: metabolite concentrations, quantification p recision, and reproducibility. J Magn Reson maging, 2004,20(3):366.
23.Vythilingam M, Charles HC, Tupler LA , et al. Focal and lateralized subcortical abnormalities in unipolar major depressive disorder: an automated multivoxel proton magnetic resonance spectroscopy study. Biol Psychiatry, 2003, 54 (7) : 744.
24.Gruber S, Frey R, Mlynarik V, et al. Quantification of metabolic differences in the frontal brain of depressive patients and controls obtained by 1H-MRS at 3 Tesla. Invest Radiol, 2003, 38 (7):403.
25.Yildiz-Yesiloglu A, Ankerst DP. Review of 1H magnetic resonance spectroscopy findings in major depressive disorder: a meta-analysis.Psychiatry Res, 2006, 147(1) : 1.
26.Young KA, Holcomb LA, Yazdani U, et al. Elevated Neuron Num-ber in the Limbic Thalamus in Major Depression. Am J Psychiatry,2004, 161 (7) : 1270.
27.林铮,李惠春,等。抑郁症患者前额叶、海马磁共振质子波谱成像的研究[J].中华精神科杂志,2005, 38(4):193-197.
28.Kato T, Inubushi T, Kato N. Magnetic resonance spectroscopy in affective disorders J Neurop sychiatry Clin Neurosci, 1998, 10: 133-147.
29.Jung RE, Brooks WM, Yeo RA, et al. Biochemical markers of intelligence: a protonMR spectroscopy study of normal human brain.Proc Biol Sci, 1999, 266: 1375-1379.
30.Miller BL, Chang L, Booth R, et al. In vivo 1H-MRS choline:correlation with in vitro chemistry/histology. Life Sci, 1996, 58:1929-1935.
31.Gup ta RK, Bhatia V, Poptani H, et al. Brain metabolite changes on in vivo proton magnetic resonance spectroscopy in children with congenital hypothyroidism1 J Pediatr, 1995, 126: 389-392.
32.Bustillo JR, Rowland LM, Lauriello J, et al. High choline concentrations in the caudate nucleus in antip sychotic-naive patients with schizophrenia1.Am J Psychiatry, 2002, 159: 130-133.
33.Navarro V, Gasto C, Lomena F, et al. Frontal cerebral perfusion after antidepressant drug treatment versus ECT in elderly patients with major depression: a 12-month follow-up control study. J Clin Psychiatry, 2004, 65: 656-661.
34.Videbech P. PET measurements of brain glucose metabolism and blood flow in major dep ressive disorder: a critical review. Acta Psychiatr Scand, 2000, 101: 11-20.
34.Kumar A, Thomas A, Lavretsky H, et al. Frontal white matter biochemical abnormalities in late-life major depression detected with proton magnetic resonance spectroscopy. Am J Psychiatry, 2002,159: 630-636.
35.Bell-McGinty S, Butters MA, Meltzer CC,et al. Brain morphometric abnormalities in geriatric depression: Longterm neurobiological effects of illness uation. Am J Psychiatry ,2002,159:1424-1427.
36.Bremner JD, Narayan M, Anderson ER, et al. Hippocampal volume reduction in major depression. Am J Psychiatry,2002, 157:115-118.
37.MacQueen GM, Campbell S, McEwen B, et al. Course of illness, hippocampal function and volume in major depression.Proc Natl Acad Sci U S A, 2003,100:1387-1392.
38.Sheline Y, Sanghavi M, Mintun M, et al. Depression duration but not age predicts hippocampal volume loss in women with recurrent major depression. J Neurosci ,1999,19:5034- 5043.
39.Sheline Y, Sanghavi M, Mintun M, et al. Depression duration but not age predicts hippocampal volume loss in women with recurrent major depression. J Neurosci ,1999, 19:5034-5043.
40.Vakili K, Pillay SS, Lafer B, et al. Hippocampal Volume in primary unipolar major depression: A magnetic resonance imaging study. Biol Psychiatry ,2000, 47:1087-1090.
41.Bowley MP, Drevets WC, Ongur D, et al. Low glial numbers in the amygdala in major depressive disorder. Biol Psychiatry ,2002, 52:404- 412.
42.Frodi T, Mesienzahl E, Zetzsche T, et al. Hippocampal changes in patients with a first episode of major depression.Am J Psychiatry ,2002,159:1112-1118.
43.Steffens DC, Byrum CE, Mcquoid DR ,et al. Hippocampal volume in geriatric depression .Biol Psychiatry ,2000,48:301-309.
44.Stephanie Campbell, Michael Marriott, Claude Nahmias, et al. Lower Hippocampal Volume in Patients Suffering From Depression: A Meta- Analysis ,2004,161:598-607.
45.Mervaala E, Fohr J, Kononen M, et al. Quantitative MRI of the hippocampus and amygdala in severe depression1 Psychol Med,2000, 30: 117-125.
46.Von Gunten A,Fox NC, Cipolotti L, et al. A volumetric study of hippocampus and amygdala in depressed patients with subjective memory problems.J Neuropsychiatry clin Neurosci ,2000,12:493-498
47.Sheline YI, Gado MH, Price JL. Amygdala core nuclei volumes are decreased in recurrent major dpression.Neuroreport, 1998,9:2023- 2028.
48.Mervaala E, Fohr J, Kononen M, et al. Quantitative MRI of the hippocamjpus and amygdala in severe depression.Psychol Med, 2000, 30:117- 125.
49.Frodl T, Meisenzahl E,Zetzsche T, et al .Enlargement of the amygdala in patients with a first episode of major depression. Biol Psychiatry, 2002,51:708- 714.
50.AshtariM, Greenwald BS, Kramer-Ginsberg E, et al. Hippocampal/amygdalavolumes in geriatric depression.Psychol Med ,1999, 29:629- 638.
51.Sapllsky RM Glucocorticoids and hippocamal atrophy in neuropsychiatric disorders. Arch Gen Psychiatry, 2000, 57: 925- 935.
53.Bourdeau I, Brad C, Noel B, et al. Loss of brain volume in endogenous Cushing's syndrome and its reversibility after correction of hypercortisolism. J Clin Endocrinol Metab,2002,87:1949-1954.
53.Carmichael ST, Price JL . Limbic connections of the orbital and medial prefrontal cortex in macaque monkeys. J Comp Neurol ,1995,363:615- 641.
54.Gould E, McEwen BS, Tanapat P, et al. Neurogenesis in the dentate gyrus of the adult tree shrew is reglated by psychosocial stress and NMDA receptor activation. J Neurosci ,1997,17:2492- 2498.
55.Alexopoulos GS, Kiosses DN, Choi SJ, et al. Frontal white matter microstructure and treatment response of late – life depression: A preliminary study. Am J Psychiatry,2002,159:1929- 1932.
1.中华医学会精神科分会主编.中国精神障碍分类与诊断标准[M]. 第三版. 济南. 山东科学技术出版社,2001:87～88.
2.汪向东.心理卫生评定量表手册[M].增订版,北京:中国心理卫生出版社,1999:220～223.
3.张捷,裴音,孙静.以针灸为主治疗抑郁症诊疗模式初探[J].北京中医,2007, 26 (3 ):137～139.
4.方向东, 蔡信诚.针药并用治疗抑郁症 52 例疗效观察[J].上海针灸杂志,2007, 26(2):19～20.
5.卢峻,时宇静,图娅. 不同频率电针对模型大鼠抗抑郁效应的比较研究. 北京中医药大学学报,2003,26(6):83-84.
6.Cheung F M. Psychological symptoms among Chinese in urban Hong Kong[J] . Social Science and Medicine ,1982,16(14):1339～1344.
7.孙华,张有志,韩毳. 电针对慢性应激抑郁模型大鼠大脑皮层 5-HT1和 5-HT2受体数量和结合性的影响[ J ]. 中国针灸, 2003,23 (9):553～554.
8.邱艳明,时宇静,图娅. 电针印堂、百会对获得性无助大鼠不同脑区内单胺类神经递质的影响. 北京中医药大学学报,2002 ,25(6):54-56.
9.李文迅,韩焱晶,陶娟,等. 电针对抑郁模型大鼠海马神经元凋亡的影响. 中国中医药信息杂志,2005,12(2):33-35.
10.淑莎尼克,图娅.电针与百优解对照治疗抑郁症的临床观察.针刺研究,2006,31(4):242-243.
11.卢峻,韩止荣,时宇静,等.电针治疗抑郁症近 10 年研究进展.针刺研究,2005,30(1):56-59.
1.Tadafumi K, Toshiro I, Nobumasa K, et al. Magnetic resonance spectroscopy in affective disorder. Journal of Neuropsychiatry and Clinical Neurosciences. 1998;10(2):133 一147.
2.侯钢,张心保,陈钰等.抑郁症患者中枢单胺类神经递质相互关系的对照研究.中国神经精神疾病杂志.2002; 28(1): 7-8.
3.郭珊,郭克锋.抑郁症的研究进展.中国临床康复.2005; 9(4): 131-133.
4. Campbell S, Maqueen G. The role of the hippocampus in the pathophysiology of major depression. J Psychiatry Neurosci. 2004; 29 (6): 417-426.
5. Hashimoto K, Shimizu E, Iyo M. Critical role of brain-derived neurotrophic factor in mood disorders. Brain Res Rev. 2004; 45 (2): 104-114.
6. Reichelt KL, Kvamme E. Histamine-dependent formation of N-acetyl-aspartyl peptides in mouse brain. J Neurochem. 1973; 21:849-859.
7. McIntosh JC, Cooper JR.Studies in the function of-acetylaspartic acid in brain. J Neurochem, 1965; 12: 825-835.
8. Simmons ML, Frondoza CG,Coyle JT. Immunocytochemical localization of N-acetyl-aspartate with monoclonal antibodies. Neuroscience. 1991;45:37-45.
9. D'Adamo AF, Gidez LI Yatsu FM. Acetyl transport mechanisms. Involvement of N-acetyl aspartic acid in de novo fatty acid biosynthesis in the developing rat brain. Exp Brain Res. 1968; 5: 267-273.
10.Shigematsu H, Okamura N, Shimeno H, et al. Purification and characterization of the heat-stable factors essential for the conversion of lignoceric acid to cerebronic acid and glutamic acid: identification of N-acetyl-L-aspartic acid. J Neurochem. 1983; 40: 814-820.
11.Sabatier J, Gilard V, Malet-Martino M, et al. Characterisation of choline compounds with in vitro 1H magnetic resonance spectroscopy for discrimination of primary brain tumours. Invest Radiol. 1999; 34: 230-235.
12.Brooks WM, Friedman SD, Stidley CA. Reproducibility of 1H MRS in vivo. Magn Reson Med.1999; 41(1): 193-197.
13.Miller BL. A review of chemical issues in 1HNMR spectroscopy: acetylaspartate, creatine and choline. NMR Bio med. 1991;4: 47-52.
14.谢长青,卢曼丽,吴光耀.脑组织质子磁共振波谱成像.武汉大学学报(医学版).2003; 24(4): 366-369.
15.Pouwels PJ, Frahm J. Regional metabolite concentrations in human brain as determined by quantitative localized proton MRS. Magn Reson Med. 1998; 39: 53-60.
16.Frahm J, Bruhn H, Gyngell ML, et al. Localized proton NMR spectroscopy in different regions of the human brain in vivo: relaxation times and concentrations of cerebral metabolites. Magn Reson Med. 1989; 11:47-63.
17.Manton DJ, Lowry M, Blackband SJ, et al. Determination of proton metabolite concentrations and relaxation parameters in normal human brain and intracranial tumors. NMR Biomed. 1995; 8: 104-112.
18.Dawn E, Saunders, Franklyn A, et al. Aging of the adult human brain: in vivo quantitation of metabolite content with proton magnetic resonance spectroscopy.MRI. 1999; 5: 711-716.
19.Petra SH. MR imaging and spectroscopy of brain development. MRI Clin North Am .2001;9(1): 1-17.
20.范国光,吴振华,刘芳,等.我国正常成人脑 1H 磁共振波谱的定量研究.中国医学影像技术.2000; 16(7): 535-538.
21.Kimbrell TA, Ketter TA, George MS, et al. Regional cerebral glucose utilization in patients with a range of severities of unipolar depression. Biol Psychiatry. 2002; 51(3):237-252.
22.Brody AL, Saxena S, Silverman DHS, et al. Brain metabolic changes in major depressive disorder from pre- to post-treatment with paroxetine. Psychiatry Res Neuroimaging. 1999; 1:127-139.
23.Jeffrey AS. In Vivo magnetic resonance spectroscopy and its application to neuropsychiatric disorders. Can J Psychiatry. 2002; 47: 315-326.
24.王祖新.抑郁症的病因学研究.中华内科杂志.1998; 37(8): 568.
25.周旋,王雪琦.谷氨酸能和γ氨基酸能系统与情感障碍.中国神经科学杂志. 2003;19(2): 130-133.
26.Moghaddam B, Adams BW. Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science. 1998; 281:1349-1352.
27.Sanacora G, Mason GF, Rothman DL, et al. Reduced cortical GABA levels in depressed patients determined by 1H-magnetic resonance spectroscopy. Arch Gen Psychiat. 1999; 56: 1043-1047.
28.Rubin RT, Phillips JJ, McCracken JT, et al. Adrenal gland column in major depression relationship to basal and stimulated pituitary-adrenal cortical axis function. Biological Psychiatry. 1996; 40(2): 89-97.
29. Duman RS, Malberg J, Nakagawa S. Neuronal plasticity and survival in mood disorders. Biol Psychiatry. 2000; 48:732-739.
30.Soares JC, Mann JJ. The anatomy of mood disorders-review of structural neuroimaging studies. Biol Psychiatry. 1997; 41:86-106.
31 Sheline YI, Mittler BL, Mintun MA. The hippocampus and depression. European Psytchiatry. 2002; 17(Supplement3): 300-305.
32.Coffey CE, Wilkinson WE, Weiner RD, et al. Quantitative cerebral anatomy in depression. A controlled magnetic resonance imaging study. Archives of General Psychiatry. 1993; 50(1):7-16.
33.Rajkowska G, Miguel-Hidalgo JJ, Wei J, et al. Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression. Biol Psychiatry. 1999; 45(9):1085 一1098.
34.Thomas F, Eva MM, Thomas Z, et al. Hippocampal changes in patients with a first episode of major depression. Am J Psychiatry. 2002; 159(7): 1112-1118.
35.Mervavla E, Folhr J, Kononen M, et al. Quantitative MRI of the hippocampus and amygdala in severe depression. Psychological Medicine. 2000; 30(1):117-125.
36.Steffens DC, Byrum CE, McQuoid DR et al. Hippocampal volume in geriatric depression. Biol Psychiat. 2000; 48: 301-309.
37.夏军,陈军,周义成,等.抑郁症患者边缘系统异常的MRI 和MRS分析.中国医学影像技术.2004; 20(6): 856-859.
38.赵晋华.抑郁症的放射性核素脑血流灌注和脑受体显像研究进展.国外医学放射医学核医学分册.1998; 22(2): 49-51.
39. Delvenne V, Goldman S, Biver F, et al. Brain hypometabolism of glucose in low weight depressed patients and in anorectic patients: a consequence of stavation? J Affective Disorders. 1997; 44: 69-77.
40.苗群,施慎逊,王占伟.功能性影像技术在抑郁症研究中的进展.中华精神科杂志.1999; 32(1): 57-59.
41. Blumberg HP, Leung HC, Wexler B, et al. Ventral prefrontal dysfunction in bipolar disorder: an fMRI study. Biol Psychiatry. 2001;49: 26.
42. Kennedy SH, Evans KR, Kruger S, et al. Changes in regional brain glucose metabolism measured with positron emission tomography after paroxetine treatment of major depression. Am J Psychiatry. 2001;158(6): 899-905.
43.Drevets WC, Price JL, Simpson JR, et al. Subgenual prefrontal cortex abnormalities in mood disorders. Nature. 1997; 386: 824-827.
44.Magaris AM, Deslandes A, Mcewen BS. Effect of antidepressant and benzodiazepine trentments on the dendritic structure of CA3 pyrimidal neurons after chronic stress. Eur J Pharmacol. 1999; 371(23):113-122.
45.Rajkowska G. Cell pathology in bipolar disorder. Bipolar Disord. 2002; 4: 105-116.
46.徐丹令,李广君,倪之挺.谷氨酸对大鼠海马兴奋毒性作用的形态学研究.解 剖学杂志.2001; 24(1): 25-27.
47. Cecil KM, DelBello MP, Morey R, et al. Frontal lobe differences in bipolar disorder as determined by proton MR spectroscopy. Bipolar Disord. 2002; 4: 357-365.
48. Winsberg ME, Sachs N, Tate DL, et al. Decreased dorsolateral prefrontal N-acetyl aspartate in bipolar disorder. Biol Psychiatry. 2000; 47: 475-481.
49.王雪琦,卢广,孙学军,等.大鼠抑郁症模型脑磁共振成像和波谱研究.中国 神经科学杂志.1999; I5(2): 162-165.
50. Tapiero H, Mathe G, Couvreur P, et al. Free amino acids in human heath andpathologies II .Glutamine and glutamate. Bio Pharmacother. 2002; 56: 446-457.
51.Steingard RJ, Yurgelun-Todd DA, Hennen J, Moore JC,et al. Increased orbitofrontal cortex levels of choline in depressed adolescents as detected by in vivo proton magnetic resonance spectroscopy. Biol Psychiatry. 2000; 48: 1053-1061.
52. Ongur D, Drevets WC, Price JL. Glial reduction in the subgenual prefrontal cortex in mood disorders. Proc Natl Acad Sci USA. 1998; 95: 13290-13295.
53. Bowley MP,Drevet WC, Ongur D. Low glial numbers in the amygdale in major depressive disorder. Biol Psychiatry. 2002; 52(5): 404-412.
54. Kato T, Hamakawa H, Shioiri T, et al. Cholinecontaining compounds detected by proton magnetic resonance spectroscopy in the basal ganglia in bipolar disorder. J Psychiatry Neurosci. 1996; 21:248-254.
55.Kumar A, Thomas A, Lavretsky H, et al. Frontal white matter biochemical abnormalities in late-life major depression detected with proton magnetic resonance spectroscopy. Am J Psychiatry. 2002; 159(4): 630-636.
56.Farchione TR,Moore GJ, Rosenberg DR. Proton magnetic resonance spectroscopic imaging in pediatric major depression. Biol Psychiatry. 2002;15;52(2): 86-92.
57.林铮,李惠春,龚向阳,等.抑郁症患者前额叶、海马磁共振质子波谱成像的研究.中华精神科杂志.2005; 38(4): 193-197.
58.Taylor W, James R, Macfall, et al. Late-life depression and micro structural abnormalities in dorsolateral prefrontal cortex white matter. Am J Psychiatry. 2004; 161(7): 1293-1296.
59.Gruber S, Frey R, Mlynarik V, Stadlbauer A, et al. Quantification of metabolic differences in the frontal brain of depressive patients and controls obtained by 1H-MRS at 3 Tesla. Invest Radiol. 2003; 38(7): 403-408. ? ? ?
1.李文迅,图娅,方芳,等. 电针对抑郁模型大鼠脑形态结构影响的磁共振成像研究. 中华物理医学与康复杂志. 2005,27(4):214-217.
2.李文迅,韩焱晶,陶娟, 等. 电针对抑郁模型大鼠海马神经元凋亡的影响. 中国中医药信息杂志,2005,12(2):33-35
3.卢峻,韩止荣,时宇静,等. 电针治疗抑郁症近 10 年研究进展. 针刺研究,2005,30(1):56-59
4.卢峻,时宇静,费宇彤,等. 电针对抑郁症模型大鼠磷酸化cAMP 反应元件结合蛋白表达的影响. 中国中医基础医学杂志,2006,12(5):380-382
5.邱艳明,时宇静,图娅. 电针印堂、百会对获得性无助大鼠不同脑区内单胺类神经递质的影响. 北京中医药大学学报,2002 ,25(6) :54-56
6.Kleinman A. 美国精神病学界关于抑郁症、躯体化障碍及神经衰弱的近代观点[J]. 国外医学精神病学分册,1980,4:212-216.
7. Cheung FM. Psychological symptoms among Chinese in urban Hong Kong[J]. Soc Science Med,1982,16:415-422.
8. 徐俊冕,张琳,江开达,等. 焦虑和抑郁的躯体化[J]. 上海精神医学,1991,3 :6-10.
9.姚道元,龚震命. 综合性医院中抑郁症及其躯体化症状的研究[J]. 四川精神卫生,1998,11:85-87.